---
title: "Parameters and Calculations Reference"
subtitle: "Comprehensive Documentation of Economic Model Variables"
format:
  html:
    toc: true
    toc-depth: 3
    number-sections: true
    code-fold: true
---

## Overview

This appendix provides comprehensive documentation of all parameters and calculations used in the economic analysis of a 1% treaty and decentralized framework for drug assessment.

**Total parameters**: 316

- External sources (peer-reviewed): 126
- Calculated values: 101
- Core definitions: 89

## Calculated Values {#sec-calculated}

Parameters derived from mathematical formulas and economic models.

### Combined Peace and Health Dividends for ROI Calculation {#sec-combined_peace_health_dividends_annual_for_roi_calc}

**Value**: $155B

Combined peace and health dividends for ROI calculation

$$
Dividend_{ann} = Cost_{soc,ann} + Benefit_{gross,ann} = \$113.55B + \$41.50B = \$155.05B
$$

**Methodology**: [../appendix/peace-dividend-calculations#peace-dividend-composition](../appendix/peace-dividend-calculations#peace-dividend-composition)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-combined_peace_health_dividends_annual_for_roi_calc.qmd >}}

{{< include ../figures/sensitivity-table-combined_peace_health_dividends_annual_for_roi_calc.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-combined_peace_health_dividends_annual_for_roi_calc.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-combined_peace_health_dividends_annual_for_roi_calc.qmd >}}


### Total Annual dFDA Operational Costs {#sec-dfda_annual_opex}

**Value**: $40M

Total annual dFDA operational costs (sum of all components: $15M + $10M + $8M + $5M + $2M)

$$
OPEX_{total} = \$15M \text{ (plat)} + \$10M \text{ (staff)} + \$8M \text{ (infra)} + \$5M \text{ (reg)} + \$2M \text{ (comm)} = \$40M
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis#opex-breakdown](../appendix/dfda-cost-benefit-analysis#opex-breakdown)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-dfda_annual_opex.qmd >}}

{{< include ../figures/sensitivity-table-dfda_annual_opex.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-dfda_annual_opex.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-dfda_annual_opex.qmd >}}


### dFDA Annual Benefit: R&D Savings {#sec-dfda_benefit_rd_only_annual}

**Value**: $41.5B

Annual dFDA benefit from R&D savings (trial cost reduction, secondary component)

$$
Benefit_{DFDA,ann} = Trials_{ann} \times Reduction = \$83.00B \times 50.0\% = \$41.50B
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis#cost-reduction](../appendix/dfda-cost-benefit-analysis#cost-reduction)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-dfda_benefit_rd_only_annual.qmd >}}

{{< include ../figures/sensitivity-table-dfda_benefit_rd_only_annual.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-dfda_benefit_rd_only_annual.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-dfda_benefit_rd_only_annual.qmd >}}


### Expected Treaty ROI (Risk-Adjusted) {#sec-dfda_expected_roi}

**Value**: 11.9k

Expected ROI for 1% treaty accounting for political success probability uncertainty. Monte Carlo samples POLITICAL_SUCCESS_PROBABILITY from beta(0.1%, 10%) distribution to generate full expected value distribution. Central value uses 1% probability.

$$
E[ROI] = ROI_{conditional} \times P_{success} = ROI_{treaty} \times 0.01
$$

**Methodology**: [Direct Calculation](#calculated)

*? Low confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-dfda_expected_roi.qmd >}}

{{< include ../figures/sensitivity-table-dfda_expected_roi.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-dfda_expected_roi.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-dfda_expected_roi.qmd >}}


### dFDA Annual Net Savings (R&D Only) {#sec-dfda_net_savings_rd_only_annual}

**Value**: $41.5B

Annual net savings from R&D cost reduction only (gross savings minus operational costs, excludes regulatory delay value)

$$
Savings_{net} = \$41.5B - \$0.04B = \$41.46B
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis#net-savings](../appendix/dfda-cost-benefit-analysis#net-savings)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-dfda_net_savings_rd_only_annual.qmd >}}

{{< include ../figures/sensitivity-table-dfda_net_savings_rd_only_annual.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-dfda_net_savings_rd_only_annual.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-dfda_net_savings_rd_only_annual.qmd >}}


### dFDA Total NPV Annual OPEX {#sec-dfda_npv_annual_opex_total}

**Value**: $40M

Total NPV annual opex (dFDA core + DIH initiatives)

$$
C_{op} = \$0.01895B + \$0.02110B = \$0.04005B \text{ (annual operational cost)}
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis#npv-costs](../appendix/dfda-cost-benefit-analysis#npv-costs)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-dfda_npv_annual_opex_total.qmd >}}

{{< include ../figures/sensitivity-table-dfda_npv_annual_opex_total.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-dfda_npv_annual_opex_total.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-dfda_npv_annual_opex_total.qmd >}}


### NPV of dFDA Benefits (R&D Only, 10-Year Discounted) {#sec-dfda_npv_benefit_rd_only}

**Value**: $275B

NPV of dFDA R&D savings only with 5-year adoption ramp (10-year horizon, most conservative financial estimate)

$$
PV_{benefits} = \sum_{t=1}^{10} \frac{NetSavings_{RD} \times \min(t,5)/5}{(1+r)^t} \approx \$249.3B \text{ (5-year linear adoption ramp)}
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis#npv-benefit](../appendix/dfda-cost-benefit-analysis#npv-benefit)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-dfda_npv_benefit_rd_only.qmd >}}

{{< include ../figures/sensitivity-table-dfda_npv_benefit_rd_only.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-dfda_npv_benefit_rd_only.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-dfda_npv_benefit_rd_only.qmd >}}


### NPV Net Benefit (R&D Only, Conservative) {#sec-dfda_npv_net_benefit_rd_only}

**Value**: $275B

NPV net benefit using R&D savings only (most conservative financial estimate, excludes regulatory delay health value)

$$
Benefit_{NPV} = \sum_{t=1}^{10} \frac{NetSavings_{RD} \times \min(t,5)/5}{(1+r)^t} \approx \$249.3B \text{ (5-year linear adoption ramp)}
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis#npv-net-benefit](../appendix/dfda-cost-benefit-analysis#npv-net-benefit)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-dfda_npv_net_benefit_rd_only.qmd >}}

{{< include ../figures/sensitivity-table-dfda_npv_net_benefit_rd_only.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-dfda_npv_net_benefit_rd_only.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-dfda_npv_net_benefit_rd_only.qmd >}}


### dFDA Present Value of Annual OPEX Over 10 Years {#sec-dfda_npv_pv_annual_opex}

**Value**: $342M

Present value of annual opex over 10 years (NPV formula)

$$
PV_{opex} = \$0.04005B \times \frac{1 - 1.08^{-10}}{0.08} \approx \$0.269B
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis#npv-calculation](../appendix/dfda-cost-benefit-analysis#npv-calculation)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-dfda_npv_pv_annual_opex.qmd >}}

{{< include ../figures/sensitivity-table-dfda_npv_pv_annual_opex.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-dfda_npv_pv_annual_opex.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-dfda_npv_pv_annual_opex.qmd >}}


### dFDA Total NPV Cost {#sec-dfda_npv_total_cost}

**Value**: $611M

Total NPV cost (upfront + PV of annual opex)

$$
TotalCost_{NPV} = \$0.26975B + \$0.269B \approx \$0.54B
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis#npv-total-cost](../appendix/dfda-cost-benefit-analysis#npv-total-cost)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-dfda_npv_total_cost.qmd >}}

{{< include ../figures/sensitivity-table-dfda_npv_total_cost.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-dfda_npv_total_cost.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-dfda_npv_total_cost.qmd >}}


### dFDA Total NPV Upfront Costs {#sec-dfda_npv_upfront_cost_total}

**Value**: $270M

Total NPV upfront costs (dFDA core + DIH initiatives)

$$
C_0 = \$0.040B + \$0.22975B = \$0.26975B \text{ (upfront cost)}
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis#npv-costs](../appendix/dfda-cost-benefit-analysis#npv-costs)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-dfda_npv_upfront_cost_total.qmd >}}

{{< include ../figures/sensitivity-table-dfda_npv_upfront_cost_total.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-dfda_npv_upfront_cost_total.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-dfda_npv_upfront_cost_total.qmd >}}


### dFDA Annual Benefit: R&D Savings {#sec-dfda_rd_gross_savings_annual}

**Value**: $41.5B

Annual dFDA benefit from R&D savings (trial cost reduction, secondary component)

$$
Benefit_{gross,ann} = Trials_{ann} \times Reduction = \$83.00B \times 50.0\% = \$41.50B
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis#cost-reduction](../appendix/dfda-cost-benefit-analysis#cost-reduction)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-dfda_rd_gross_savings_annual.qmd >}}

{{< include ../figures/sensitivity-table-dfda_rd_gross_savings_annual.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-dfda_rd_gross_savings_annual.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-dfda_rd_gross_savings_annual.qmd >}}


### Daily R&D Savings from Trial Cost Reduction {#sec-dfda_rd_savings_daily}

**Value**: $114M

Daily R&D savings from trial cost reduction (opportunity cost of delay)

$$
Savings_{daily} = \frac{\$41.5B}{365} = \$113.7M
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis#daily-opportunity-cost-of-inaction](../appendix/dfda-cost-benefit-analysis#daily-opportunity-cost-of-inaction)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-dfda_rd_savings_daily.qmd >}}

{{< include ../figures/sensitivity-table-dfda_rd_savings_daily.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-dfda_rd_savings_daily.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-dfda_rd_savings_daily.qmd >}}


### ROI from dFDA R&D Savings Only {#sec-dfda_roi_rd_only}

**Value**: 451 ratio

ROI from dFDA R&D savings only (10-year NPV, most conservative estimate)

$$
ROI_{RD} = \frac{\$249.3B}{\$0.54B} \approx 463
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis#roi-simple](../appendix/dfda-cost-benefit-analysis#roi-simple)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-dfda_roi_rd_only.qmd >}}

{{< include ../figures/sensitivity-table-dfda_roi_rd_only.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-dfda_roi_rd_only.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-dfda_roi_rd_only.qmd >}}


### dFDA Simple ROI Without NPV Adjustment {#sec-dfda_roi_simple}

**Value**: 1.04k ratio

Simple ROI without NPV adjustment (gross savings / annual opex)

$$
ROI_{DFDA} = \frac{Benefit_{gross,ann}}{Cost_{DFDA,ann}} = \frac{\$41.50B}{\$40.0M} = 1{,}038
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis#roi-simple](../appendix/dfda-cost-benefit-analysis#roi-simple)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-dfda_roi_simple.qmd >}}

{{< include ../figures/sensitivity-table-dfda_roi_simple.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-dfda_roi_simple.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-dfda_roi_simple.qmd >}}


### dFDA Maximum Trials per Year {#sec-dfda_trials_per_year_capacity}

**Value**: 75.4k trials/year

Maximum trials per year possible with trial capacity multiplier

$$
Capacity_{DFDA} = Trials_{curr} \times Multiplier = 3{,}300 \times 22.85 = 75{,}392
$$

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-dfda_trials_per_year_capacity.qmd >}}

{{< include ../figures/sensitivity-table-dfda_trials_per_year_capacity.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-dfda_trials_per_year_capacity.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-dfda_trials_per_year_capacity.qmd >}}


### Patients Fundable Annually {#sec-dih_patients_fundable_annually}

**Value**: 43.4M patients/year

Number of patients fundable annually at RECOVERY trial cost

$$
Fundable_{ann} = \frac{Treasury_{ann}}{Cost} = \frac{\$21.70B}{\$500} = 43.4M
$$

**Methodology**: [../economics/economics#funding-allocation](../economics/economics#funding-allocation)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-dih_patients_fundable_annually.qmd >}}

{{< include ../figures/sensitivity-table-dih_patients_fundable_annually.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-dih_patients_fundable_annually.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-dih_patients_fundable_annually.qmd >}}


### DIH Annual Funding for Pragmatic Clinical Trials {#sec-dih_treasury_to_medical_research_annual}

**Value**: $21.7B

Annual funding for pragmatic clinical trials (treaty funding minus VICTORY Bond payouts and IAB political incentive mechanism)

$$
ResearchFunding = \$27.18B - \$2.718B - \$2.718B = \$21.744B
$$

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-dih_treasury_to_medical_research_annual.qmd >}}

{{< include ../figures/sensitivity-table-dih_treasury_to_medical_research_annual.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-dih_treasury_to_medical_research_annual.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-dih_treasury_to_medical_research_annual.qmd >}}


### Annual Clinical Trial Patient Subsidies {#sec-dih_treasury_trial_subsidies_annual}

**Value**: $21.7B

Annual clinical trial patient subsidies (all medical research funds after dFDA operations)

$$
TrialSubsidies = \$24.462B - \$0.04B = \$24.422B
$$

**Methodology**: [../economics/economics#funding-allocation](../economics/economics#funding-allocation)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-dih_treasury_trial_subsidies_annual.qmd >}}

{{< include ../figures/sensitivity-table-dih_treasury_trial_subsidies_annual.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-dih_treasury_trial_subsidies_annual.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-dih_treasury_trial_subsidies_annual.qmd >}}


### Total DALYs Lost from Disease Eradication Delay {#sec-disease_eradication_delay_dalys}

**Value**: 7.94B DALYs

Total Disability-Adjusted Life Years lost from disease eradication delay (PRIMARY estimate)

$$
DALY_{total} = 7.03B \text{ (YLL)} + 0.87B \text{ (YLD)} = 7.90B
$$

**Methodology**: [../appendix/regulatory-mortality-analysis#daly-calculation](../appendix/regulatory-mortality-analysis#daly-calculation)

*~ Medium confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-disease_eradication_delay_dalys.qmd >}}

{{< include ../figures/sensitivity-table-disease_eradication_delay_dalys.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-disease_eradication_delay_dalys.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-disease_eradication_delay_dalys.qmd >}}


### Total Deaths from Disease Eradication Delay {#sec-disease_eradication_delay_deaths_total}

**Value**: 416M deaths

Total eventually avoidable deaths from delaying disease eradication by 8.2 years (PRIMARY estimate, conservative). Excludes fundamentally unavoidable deaths (primarily accidents ~7.9%).

$$
D_{total} = 54.75M \text{ (annual)} \times 8.2 \text{ (lag)} \times 92.1\% \text{ (avoidable)} = 413.4M
$$

**Methodology**: [../appendix/regulatory-mortality-analysis#disease-eradication-delay](../appendix/regulatory-mortality-analysis#disease-eradication-delay)

*~ Medium confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-disease_eradication_delay_deaths_total.qmd >}}

{{< include ../figures/sensitivity-table-disease_eradication_delay_deaths_total.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-disease_eradication_delay_deaths_total.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-disease_eradication_delay_deaths_total.qmd >}}


### Total Economic Loss from Disease Eradication Delay {#sec-disease_eradication_delay_economic_loss}

**Value**: $1.19 quadrillion

Total economic loss from delaying disease eradication by 8.2 years (PRIMARY estimate, 2024 USD). Values global DALYs at standardized US/International normative rate ($150k) rather than local ability-to-pay, representing the full human capital loss.

$$
Loss = 7.90B \times \$150k = \$1.185\text{ quadrillion}
$$

**Methodology**: [../appendix/regulatory-mortality-analysis#economic-valuation](../appendix/regulatory-mortality-analysis#economic-valuation)

*~ Medium confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-disease_eradication_delay_economic_loss.qmd >}}

{{< include ../figures/sensitivity-table-disease_eradication_delay_economic_loss.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-disease_eradication_delay_economic_loss.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-disease_eradication_delay_economic_loss.qmd >}}


### Years Lived with Disability During Disease Eradication Delay {#sec-disease_eradication_delay_yld}

**Value**: 873M years

Years Lived with Disability during disease eradication delay (PRIMARY estimate)

$$
Delay_{dis} = Deaths_{total} \times Deaths \times Chronic = 415.9M \times 6 \times 0.35 = 873.3M
$$

**Methodology**: [../appendix/regulatory-mortality-analysis#daly-calculation](../appendix/regulatory-mortality-analysis#daly-calculation)

*~ Medium confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-disease_eradication_delay_yld.qmd >}}

{{< include ../figures/sensitivity-table-disease_eradication_delay_yld.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-disease_eradication_delay_yld.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-disease_eradication_delay_yld.qmd >}}


### Years of Life Lost from Disease Eradication Delay {#sec-disease_eradication_delay_yll}

**Value**: 7.07B years

Years of Life Lost from disease eradication delay deaths (PRIMARY estimate)

$$
YLL = 413.4M \times 17 \text{ (years lost)} = 7.03B
$$

**Methodology**: [../appendix/regulatory-mortality-analysis#daly-calculation](../appendix/regulatory-mortality-analysis#daly-calculation)

*~ Medium confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-disease_eradication_delay_yll.qmd >}}

{{< include ../figures/sensitivity-table-disease_eradication_delay_yll.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-disease_eradication_delay_yll.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-disease_eradication_delay_yll.qmd >}}


### Total Deaths from Disease Eradication + Innovation Acceleration {#sec-disease_eradication_plus_acceleration_deaths_total}

**Value**: 898M deaths

Total deaths from disease eradication delay plus innovation acceleration (OPTIMISTIC UPPER BOUND). Represents additional deaths avoided beyond lag elimination through innovation cascade effects: faster development cycles, lower barriers enabling more drugs, earlier phase starts. The 2× multiplier is supported by research showing 50% timeline reductions achievable (Nature 2023) and adaptive trials generating millions of additional life-years (Woods et al. 2024). Based on (150K daily × 365 × 2) × 8.2 years.

$$
D_{total} = (54.75M \times 2) \times 8.2 = 898M
$$

**Methodology**: [../references#pharmaceutical-innovation-acceleration-economics](../references#pharmaceutical-innovation-acceleration-economics)

*? Low confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-disease_eradication_plus_acceleration_deaths_total.qmd >}}

{{< include ../figures/sensitivity-table-disease_eradication_plus_acceleration_deaths_total.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-disease_eradication_plus_acceleration_deaths_total.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-disease_eradication_plus_acceleration_deaths_total.qmd >}}


### Total Economic Loss from Disease Eradication + Innovation Acceleration {#sec-disease_eradication_plus_acceleration_economic_loss_total}

**Value**: $2.38 quadrillion

Total economic loss from disease eradication delay plus innovation acceleration (OPTIMISTIC UPPER BOUND). The 2× multiplier represents combined timeline and volume effects from eliminating Phase 2-4 cost barriers. Research shows: (1) Timeline acceleration of 50% achievable through AI/tech (Nature 2023), (2) Adaptive trials can reduce costs $2.6B→$2.2B, generating 3.5M additional life-years (Woods et al. 2024, Health Economics), (3) Cost barrier elimination enables more drugs to reach viability. The 2× factor conservatively represents either 2× timeline acceleration OR 1.5× timeline × 1.33× volume. Dynamic efficiency framework suggests optimal manufacturer value share ~20% maximizes long-term population health (Woods 2024).

$$
Loss_{total} = \$1,286T \times 2 = \$2,572T
$$

**Methodology**: [../references#pharmaceutical-innovation-acceleration-economics](../references#pharmaceutical-innovation-acceleration-economics)

*? Low confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-disease_eradication_plus_acceleration_economic_loss_total.qmd >}}

{{< include ../figures/sensitivity-table-disease_eradication_plus_acceleration_economic_loss_total.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-disease_eradication_plus_acceleration_economic_loss_total.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-disease_eradication_plus_acceleration_economic_loss_total.qmd >}}


### Coverage Factor of Treaty Funding vs dFDA OPEX {#sec-dividend_coverage_factor}

**Value**: 680 ratio

Coverage factor of treaty funding vs dFDA opex (sustainability margin)

$$
Coverage = \$27.18B / \$0.04B = 679x
$$

**Methodology**: [../strategy/roadmap#sustainability](../strategy/roadmap#sustainability)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-dividend_coverage_factor.qmd >}}

{{< include ../figures/sensitivity-table-dividend_coverage_factor.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-dividend_coverage_factor.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-dividend_coverage_factor.qmd >}}


### Drug Cost Increase: 1980s to Current {#sec-drug_cost_increase_1980s_to_current_multiplier}

**Value**: 13.4 ratio

Drug development cost increase from 1980s to current ($194M → $2.6B = 13.4x)

$$
Multiplier_{curr} = \frac{Cost_{curr}}{Cost_{80s}} = \frac{\$2.60B}{\$194.0M} = 13.4
$$

**Methodology**: [pre-1962-drug-costs-timeline](../references#pre-1962-drug-costs-timeline)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-drug_cost_increase_1980s_to_current_multiplier.qmd >}}

{{< include ../figures/sensitivity-table-drug_cost_increase_1980s_to_current_multiplier.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-drug_cost_increase_1980s_to_current_multiplier.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-drug_cost_increase_1980s_to_current_multiplier.qmd >}}


### Drug Cost Increase: Pre-1962 to Current {#sec-drug_cost_increase_pre1962_to_current_multiplier}

**Value**: 52 ratio

Drug development cost increase from pre-1962 to current ($50M → $2.6B = 52x)

$$
Multiplier_{curr} = \frac{Cost_{curr}}{Cost_{pre62}} = \frac{\$2.60B}{\$50.0M} = 52
$$

**Methodology**: [pre-1962-drug-costs-timeline](../references#pre-1962-drug-costs-timeline)

*~ Medium confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-drug_cost_increase_pre1962_to_current_multiplier.qmd >}}

{{< include ../figures/sensitivity-table-drug_cost_increase_pre1962_to_current_multiplier.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-drug_cost_increase_pre1962_to_current_multiplier.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-drug_cost_increase_pre1962_to_current_multiplier.qmd >}}


### FDA to Oxford RECOVERY Trial Time Multiplier {#sec-fda_to_oxford_recovery_trial_time_multiplier}

**Value**: 36.4 ratio

FDA approval timeline vs Oxford RECOVERY trial (9.1 years ÷ 3 months = 36x slower)

$$
\frac{9.1 \text{ years} \times 12 \text{ months/year}}{3 \text{ months}} = 36.4
$$

**Methodology**: [recovery-trial-82x-cost-reduction](../references#recovery-trial-82x-cost-reduction)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-fda_to_oxford_recovery_trial_time_multiplier.qmd >}}

{{< include ../figures/sensitivity-table-fda_to_oxford_recovery_trial_time_multiplier.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-fda_to_oxford_recovery_trial_time_multiplier.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-fda_to_oxford_recovery_trial_time_multiplier.qmd >}}


### Total Annual Conflict Deaths Globally {#sec-global_annual_conflict_deaths_total}

**Value**: 245k deaths/year

Total annual conflict deaths globally (sum of combat, terror, state violence)

$$
Deaths_{total} = 233,600 \text{ (combat)} + 8,300 \text{ (terror)} + 2,700 \text{ (state)} = 244,600
$$

**Methodology**: [../problem/cost-of-war#death-accounting](../problem/cost-of-war#death-accounting)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-global_annual_conflict_deaths_total.qmd >}}

{{< include ../figures/sensitivity-table-global_annual_conflict_deaths_total.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-global_annual_conflict_deaths_total.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-global_annual_conflict_deaths_total.qmd >}}


### Annual Cost of Combat Deaths {#sec-global_annual_human_cost_active_combat}

**Value**: $2.34T

Annual cost of combat deaths (deaths × VSL)

$$
Cost_{human,ann} = Deaths_{combat,ann} \times Value = 233{,}600 \times \$10.0M = \$2.34T
$$

**Methodology**: [../problem/cost-of-war#human-cost](../problem/cost-of-war#human-cost)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-global_annual_human_cost_active_combat.qmd >}}

{{< include ../figures/sensitivity-table-global_annual_human_cost_active_combat.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-global_annual_human_cost_active_combat.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-global_annual_human_cost_active_combat.qmd >}}


### Annual Cost of State Violence Deaths {#sec-global_annual_human_cost_state_violence}

**Value**: $27B

Annual cost of state violence deaths (deaths × VSL)

$$
Cost_{human,ann} = Deaths_{ann} \times Value = 2{,}700 \times \$10.0M = \$27.00B
$$

**Methodology**: [../problem/cost-of-war#human-cost](../problem/cost-of-war#human-cost)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-global_annual_human_cost_state_violence.qmd >}}

{{< include ../figures/sensitivity-table-global_annual_human_cost_state_violence.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-global_annual_human_cost_state_violence.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-global_annual_human_cost_state_violence.qmd >}}


### Annual Cost of Terror Deaths {#sec-global_annual_human_cost_terror_attacks}

**Value**: $83B

Annual cost of terror deaths (deaths × VSL)

$$
Cost_{human,ann} = Deaths_{terror,ann} \times Value = 8{,}300 \times \$10.0M = \$83.00B
$$

**Methodology**: [../problem/cost-of-war#human-cost](../problem/cost-of-war#human-cost)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-global_annual_human_cost_terror_attacks.qmd >}}

{{< include ../figures/sensitivity-table-global_annual_human_cost_terror_attacks.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-global_annual_human_cost_terror_attacks.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-global_annual_human_cost_terror_attacks.qmd >}}


### Total Annual Human Life Losses from Conflict {#sec-global_annual_human_life_losses_conflict}

**Value**: $2.45T

Total annual human life losses from conflict (sum of combat, terror, state violence)

$$
Cost_{human} = \$2,336B \text{ (combat)} + \$83B \text{ (terror)} + \$27B \text{ (state)} = \$2,446B
$$

**Methodology**: [../problem/cost-of-war#human-cost](../problem/cost-of-war#human-cost)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-global_annual_human_life_losses_conflict.qmd >}}

{{< include ../figures/sensitivity-table-global_annual_human_life_losses_conflict.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-global_annual_human_life_losses_conflict.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-global_annual_human_life_losses_conflict.qmd >}}


### Total Annual Infrastructure Destruction {#sec-global_annual_infrastructure_destruction_conflict}

**Value**: $1.88T

Total annual infrastructure destruction (sum of transportation, energy, communications, water, education, healthcare)

$$
Infra_{damage} = \$487B \text{ (trans)} + \$422B \text{ (nrg)} + \$298B \text{ (comms)} + \$268B \text{ (water)} + \$235B \text{ (edu)} + \$166B \text{ (hlth)} = \$1,875B
$$

**Methodology**: [../problem/cost-of-war#infrastructure-damage](../problem/cost-of-war#infrastructure-damage)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-global_annual_infrastructure_destruction_conflict.qmd >}}

{{< include ../figures/sensitivity-table-global_annual_infrastructure_destruction_conflict.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-global_annual_infrastructure_destruction_conflict.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-global_annual_infrastructure_destruction_conflict.qmd >}}


### Total Annual Trade Disruption {#sec-global_annual_trade_disruption_conflict}

**Value**: $616B

Total annual trade disruption (sum of shipping, supply chain, energy prices, currency instability)

$$
Trade_{disruption} = \$247B \text{ (ship)} + \$187B \text{ (supply)} + \$125B \text{ (nrg)} + \$57B \text{ (curr)} = \$616B
$$

**Methodology**: [../problem/cost-of-war#trade-disruption](../problem/cost-of-war#trade-disruption)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-global_annual_trade_disruption_conflict.qmd >}}

{{< include ../figures/sensitivity-table-global_annual_trade_disruption_conflict.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-global_annual_trade_disruption_conflict.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-global_annual_trade_disruption_conflict.qmd >}}


### Total Annual Direct War Costs {#sec-global_annual_war_direct_costs_total}

**Value**: $7.66T

Total annual direct war costs (military spending + infrastructure + human life + trade disruption)

$$
DirectCosts = \$2,718B \text{ (mil)} + \$1,875B \text{ (infra)} + \$2,446B \text{ (human)} + \$616B \text{ (trade)} = \$7,655B
$$

**Methodology**: [../problem/cost-of-war#direct-costs](../problem/cost-of-war#direct-costs)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-global_annual_war_direct_costs_total.qmd >}}

{{< include ../figures/sensitivity-table-global_annual_war_direct_costs_total.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-global_annual_war_direct_costs_total.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-global_annual_war_direct_costs_total.qmd >}}


### Total Annual Indirect War Costs {#sec-global_annual_war_indirect_costs_total}

**Value**: $3.70T

Total annual indirect war costs (opportunity cost + veterans + refugees + environment + mental health + lost productivity)

$$
IndirectCosts = \$2.7T \text{ (opp cost)} + \$200B \text{ (vet)} + \$150B \text{ (ref)} + \$100B \text{ (env)} + \$232B \text{ (ptsd)} + \$300B \text{ (hum cap)} = \$3.7T
$$

**Methodology**: [../problem/cost-of-war#indirect-costs](../problem/cost-of-war#indirect-costs)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-global_annual_war_indirect_costs_total.qmd >}}

{{< include ../figures/sensitivity-table-global_annual_war_indirect_costs_total.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-global_annual_war_indirect_costs_total.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-global_annual_war_indirect_costs_total.qmd >}}


### Total Annual Cost of War Worldwide {#sec-global_annual_war_total_cost}

**Value**: $11.4T

Total annual cost of war worldwide (direct + indirect costs)

$$
TotalWarCost = \$7,655B \text{ (direct)} + \$3,700B \text{ (indirect)} = \$11,355B
$$

**Methodology**: [../problem/cost-of-war#total-cost](../problem/cost-of-war#total-cost)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-global_annual_war_total_cost.qmd >}}

{{< include ../figures/sensitivity-table-global_annual_war_total_cost.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-global_annual_war_total_cost.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-global_annual_war_total_cost.qmd >}}


### Cost per Life Saved by Medical Research {#sec-global_cost_per_life_saved_med_research_annual}

**Value**: $16.1K

Cost per life saved by medical research

$$
CostPerLifeSaved = \frac{\$67.5B \times 10^9}{4,200,000} \approx \$16,071
$$

**Methodology**: [../problem/cost-of-war#grotesque-mathematics](../problem/cost-of-war#grotesque-mathematics)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-global_cost_per_life_saved_med_research_annual.qmd >}}

{{< include ../figures/sensitivity-table-global_cost_per_life_saved_med_research_annual.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-global_cost_per_life_saved_med_research_annual.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-global_cost_per_life_saved_med_research_annual.qmd >}}


### Total Economic Burden of Disease Globally {#sec-global_disease_economic_burden_annual}

**Value**: $109T

Total economic burden of disease globally (medical + productivity + mortality)

$$
Burden_{ann} = Cost_{direct,ann} + Loss_{human,ann} + Loss_{ann} = \$9.90T + \$94.20T + \$5.00T = \$109.10T
$$

**Methodology**: [disease-economic-burden-109t](../references#disease-economic-burden-109t)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-global_disease_economic_burden_annual.qmd >}}

{{< include ../figures/sensitivity-table-global_disease_economic_burden_annual.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-global_disease_economic_burden_annual.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-global_disease_economic_burden_annual.qmd >}}


### Annual Global Industry Spending on Clinical Trials {#sec-global_industry_clinical_trials_spending_annual}

**Value**: $78.5B

Annual global industry spending on clinical trials (Total - Government)

$$
Trials_{ann} = Trials_{ann} - Trials_{ann} = \$83.00B - \$4.50B = \$78.50B
$$

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-global_industry_clinical_trials_spending_annual.qmd >}}

{{< include ../figures/sensitivity-table-global_industry_clinical_trials_spending_annual.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-global_industry_clinical_trials_spending_annual.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-global_industry_clinical_trials_spending_annual.qmd >}}


### Per Capita Military Spending Globally {#sec-global_military_spending_per_capita_annual}

**Value**: $340

Per capita military spending globally

$$
PerCapita_{military} = \$2,718B / 8.0B = \$339.75
$$

**Methodology**: [../problem/cost-of-war#per-capita](../problem/cost-of-war#per-capita)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-global_military_spending_per_capita_annual.qmd >}}

{{< include ../figures/sensitivity-table-global_military_spending_per_capita_annual.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-global_military_spending_per_capita_annual.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-global_military_spending_per_capita_annual.qmd >}}


### Global Military Spending After 1% Treaty Reduction {#sec-global_military_spending_post_treaty_annual_2024}

**Value**: $2.69T

Global military spending after 1% treaty reduction

$$
PostTreaty_{military} = \$2,718B \times 0.99 = \$2,690.82B
$$

**Methodology**: [../strategy/treaty-adoption-strategy#post-treaty](../strategy/treaty-adoption-strategy#post-treaty)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-global_military_spending_post_treaty_annual_2024.qmd >}}

{{< include ../figures/sensitivity-table-global_military_spending_post_treaty_annual_2024.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-global_military_spending_post_treaty_annual_2024.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-global_military_spending_post_treaty_annual_2024.qmd >}}


### Total Annual Cost of War and Disease with All Externalities {#sec-global_total_health_and_war_cost_annual}

**Value**: $129T

Total annual cost of war and disease with all externalities (direct + indirect costs for both)

$$
Cost_{total} = Cost_{war,total} + Burden_{ann} + Spending_{sympt,ann} = \$11.36T + \$109.10T + \$8.20T = \$128.66T
$$

**Methodology**: [../appendix/humanity-budget-overview](../appendix/humanity-budget-overview)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-global_total_health_and_war_cost_annual.qmd >}}

{{< include ../figures/sensitivity-table-global_total_health_and_war_cost_annual.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-global_total_health_and_war_cost_annual.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-global_total_health_and_war_cost_annual.qmd >}}


### Total Deaths from Historical Progress Delays {#sec-historical_progress_deaths_total}

**Value**: 98.4M deaths

Total deaths from delaying existing drugs over 8.2-year efficacy lag (CONSERVATIVE FLOOR). One-time impact of eliminating Phase 2-4 testing delay for drugs already approved 1962-2024. Based on 12M deaths/year rate × 8.2 years.

$$
D_{total} = 12M \times 8.2 = 98.4M
$$

**Methodology**: [../appendix/regulatory-mortality-analysis#historical-progress](../appendix/regulatory-mortality-analysis#historical-progress)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-historical_progress_deaths_total.qmd >}}

{{< include ../figures/sensitivity-table-historical_progress_deaths_total.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-historical_progress_deaths_total.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-historical_progress_deaths_total.qmd >}}


### Total Economic Loss from Historical Progress Delays {#sec-historical_progress_economic_loss_total}

**Value**: $251T

Total economic loss from delaying existing drugs over 8.2-year efficacy lag (CONSERVATIVE FLOOR). One-time benefit of eliminating Phase 2-4 delay.

$$
Loss_{total} = 98.4M \times 17 \times \$150k = \$251T
$$

**Methodology**: [../appendix/regulatory-mortality-analysis#historical-progress](../appendix/regulatory-mortality-analysis#historical-progress)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-historical_progress_economic_loss_total.qmd >}}

{{< include ../figures/sensitivity-table-historical_progress_economic_loss_total.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-historical_progress_economic_loss_total.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-historical_progress_economic_loss_total.qmd >}}


### Annual IAB Political Incentive Funding {#sec-iab_political_incentive_funding_annual}

**Value**: $2.72B

Annual funding for IAB political incentive mechanism (independent expenditures supporting high-scoring politicians, post-office fellowship endowments, Public Good Score infrastructure)

$$
IABFunding = \$27.18B \times 0.10 = \$2.718B
$$

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-iab_political_incentive_funding_annual.qmd >}}

{{< include ../figures/sensitivity-table-iab_political_incentive_funding_annual.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-iab_political_incentive_funding_annual.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-iab_political_incentive_funding_annual.qmd >}}


### Ratio of Industry to Government Clinical Trials Spending {#sec-industry_vs_government_clinical_trials_spending_ratio}

**Value**: 17.4 ratio

Ratio of Industry to Government spending on clinical trials (approx 90/10 split)

*Formula*: `(TOTAL - GOVT) / GOVT`

**Methodology**: [industry-vs-government-trial-spending-split](../references#industry-vs-government-trial-spending-split)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-industry_vs_government_clinical_trials_spending_ratio.qmd >}}

{{< include ../figures/sensitivity-table-industry_vs_government_clinical_trials_spending_ratio.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-industry_vs_government_clinical_trials_spending_ratio.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-industry_vs_government_clinical_trials_spending_ratio.qmd >}}


### Medical Research Spending as Percentage of Total Disease Burden {#sec-medical_research_pct_of_disease_burden}

**Value**: 0.0525%

Medical research spending as percentage of total disease burden

$$
\frac{\$67.5\text{B}}{\$128.6\text{T}} = 0.052\%
$$

**Methodology**: [../economics/economics](../economics/economics)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-medical_research_pct_of_disease_burden.qmd >}}

{{< include ../figures/sensitivity-table-medical_research_pct_of_disease_burden.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-medical_research_pct_of_disease_burden.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-medical_research_pct_of_disease_burden.qmd >}}


### Ratio of Military to Government Clinical Trials Spending {#sec-military_to_government_clinical_trials_spending_ratio}

**Value**: 604 ratio

Ratio of global military spending to government clinical trials spending

$$
\text{Ratio} = \frac{\$2.7T}{\$4.5B} \approx 600\times
$$

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-military_to_government_clinical_trials_spending_ratio.qmd >}}

{{< include ../figures/sensitivity-table-military_to_government_clinical_trials_spending_ratio.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-military_to_government_clinical_trials_spending_ratio.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-military_to_government_clinical_trials_spending_ratio.qmd >}}


### Ratio of Military Spending to Medical Research Spending {#sec-military_vs_medical_research_ratio}

**Value**: 40.3 ratio

Ratio of military spending to medical research spending

$$
Ratio = \frac{\$2,718B}{\$67.5B} \approx 40.3:1
$$

**Methodology**: [../problem/cost-of-war#misallocation](../problem/cost-of-war#misallocation)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-military_vs_medical_research_ratio.qmd >}}

{{< include ../figures/sensitivity-table-military_vs_medical_research_ratio.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-military_vs_medical_research_ratio.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-military_vs_medical_research_ratio.qmd >}}


### Misallocation Factor: Cost to Kill vs Cost to Save {#sec-misallocation_factor_death_vs_saving}

**Value**: 2.89k ratio

Misallocation factor: cost to kill vs cost to save

$$
Misallocation = \frac{\$46.4M}{\$16,071} \approx 2,889x
$$

**Methodology**: [../problem/cost-of-war#grotesque-mathematics](../problem/cost-of-war#grotesque-mathematics)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-misallocation_factor_death_vs_saving.qmd >}}

{{< include ../figures/sensitivity-table-misallocation_factor_death_vs_saving.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-misallocation_factor_death_vs_saving.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-misallocation_factor_death_vs_saving.qmd >}}


### Annual Peace Dividend from 1% Reduction in Total War Costs {#sec-peace_dividend_annual_societal_benefit}

**Value**: $114B

Annual peace dividend from 1% reduction in total war costs

$$
Cost_{soc,ann} = Cost_{war,total} \times Reduction_{treaty} = \$11.36T \times 1.0\% = \$113.55B
$$

**Methodology**: [../appendix/peace-dividend-calculations](../appendix/peace-dividend-calculations)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-peace_dividend_annual_societal_benefit.qmd >}}

{{< include ../figures/sensitivity-table-peace_dividend_annual_societal_benefit.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-peace_dividend_annual_societal_benefit.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-peace_dividend_annual_societal_benefit.qmd >}}


### Conflict Reduction Benefits from 1% Less Military Spending {#sec-peace_dividend_conflict_reduction}

**Value**: $86.4B

Conflict reduction benefits from 1% less military spending (lower confidence - assumes proportional relationship)

$$
PeaceDividend_{conflict} = \$113.55B - \$27.18B = \$86.37B
$$

**Methodology**: [Direct Calculation](#calculated)

*? Low confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-peace_dividend_conflict_reduction.qmd >}}

{{< include ../figures/sensitivity-table-peace_dividend_conflict_reduction.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-peace_dividend_conflict_reduction.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-peace_dividend_conflict_reduction.qmd >}}


### Annual Savings from 1% Reduction in Direct War Costs {#sec-peace_dividend_direct_costs}

**Value**: $76.5B

Annual savings from 1% reduction in direct war costs

$$
Cost_{direct,peace} = Cost_{direct,total} \times Reduction_{treaty} = \$7.66T \times 1.0\% = \$76.55B
$$

**Methodology**: [../economics/peace-dividend](../economics/peace-dividend)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-peace_dividend_direct_costs.qmd >}}

{{< include ../figures/sensitivity-table-peace_dividend_direct_costs.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-peace_dividend_direct_costs.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-peace_dividend_direct_costs.qmd >}}


### Annual Savings from 1% Reduction in Environmental Damage {#sec-peace_dividend_environmental}

**Value**: $1.00B

Annual savings from 1% reduction in environmental damage

$$
Savings_{env,peace} = Cost_{env,ann} \times Reduction_{treaty} = \$100.00B \times 1.0\% = \$1.00B
$$

**Methodology**: [../economics/peace-dividend](../economics/peace-dividend)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-peace_dividend_environmental.qmd >}}

{{< include ../figures/sensitivity-table-peace_dividend_environmental.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-peace_dividend_environmental.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-peace_dividend_environmental.qmd >}}


### Annual Savings from 1% Reduction in Human Casualties {#sec-peace_dividend_human_casualties}

**Value**: $24.5B

Annual savings from 1% reduction in human casualties

$$
Savings_{human,peace} = Loss_{human,ann} \times Reduction_{treaty} = \$2.45T \times 1.0\% = \$24.46B
$$

**Methodology**: [../economics/peace-dividend](../economics/peace-dividend)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-peace_dividend_human_casualties.qmd >}}

{{< include ../figures/sensitivity-table-peace_dividend_human_casualties.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-peace_dividend_human_casualties.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-peace_dividend_human_casualties.qmd >}}


### Annual Savings from 1% Reduction in Indirect War Costs {#sec-peace_dividend_indirect_costs}

**Value**: $37B

Annual savings from 1% reduction in indirect war costs

$$
Cost_{indirect,peace} = Cost_{indirect,total} \times Reduction_{treaty} = \$3.70T \times 1.0\% = \$37.00B
$$

**Methodology**: [../economics/peace-dividend](../economics/peace-dividend)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-peace_dividend_indirect_costs.qmd >}}

{{< include ../figures/sensitivity-table-peace_dividend_indirect_costs.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-peace_dividend_indirect_costs.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-peace_dividend_indirect_costs.qmd >}}


### Annual Savings from 1% Reduction in Infrastructure Destruction {#sec-peace_dividend_infrastructure}

**Value**: $18.8B

Annual savings from 1% reduction in infrastructure destruction

$$
Savings_{infra,peace} = Infrastructure_{global} \times Reduction_{treaty} = \$1.88T \times 1.0\% = \$18.75B
$$

**Methodology**: [../economics/peace-dividend](../economics/peace-dividend)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-peace_dividend_infrastructure.qmd >}}

{{< include ../figures/sensitivity-table-peace_dividend_infrastructure.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-peace_dividend_infrastructure.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-peace_dividend_infrastructure.qmd >}}


### Annual Savings from 1% Reduction in Lost Economic Growth {#sec-peace_dividend_lost_economic_growth}

**Value**: $27.2B

Annual savings from 1% reduction in lost economic growth

$$
Savings_{lost_econ,peace} = Cost_{mil,ann} \times Reduction_{treaty} = \$2.72T \times 1.0\% = \$27.18B
$$

**Methodology**: [../economics/peace-dividend](../economics/peace-dividend)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-peace_dividend_lost_economic_growth.qmd >}}

{{< include ../figures/sensitivity-table-peace_dividend_lost_economic_growth.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-peace_dividend_lost_economic_growth.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-peace_dividend_lost_economic_growth.qmd >}}


### Annual Savings from 1% Reduction in Lost Human Capital {#sec-peace_dividend_lost_human_capital}

**Value**: $3.00B

Annual savings from 1% reduction in lost human capital

$$
Savings_{human,peace} = Lost_{global} \times Reduction_{treaty} = \$300.00B \times 1.0\% = \$3.00B
$$

**Methodology**: [../economics/peace-dividend](../economics/peace-dividend)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-peace_dividend_lost_human_capital.qmd >}}

{{< include ../figures/sensitivity-table-peace_dividend_lost_human_capital.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-peace_dividend_lost_human_capital.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-peace_dividend_lost_human_capital.qmd >}}


### Annual Savings from 1% Reduction in PTSD and Mental Health Costs {#sec-peace_dividend_ptsd}

**Value**: $2.32B

Annual savings from 1% reduction in PTSD and mental health costs

$$
Cost_{PTSD,peace} = Cost_{ann} \times Reduction_{treaty} = \$232.00B \times 1.0\% = \$2.32B
$$

**Methodology**: [../economics/peace-dividend](../economics/peace-dividend)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-peace_dividend_ptsd.qmd >}}

{{< include ../figures/sensitivity-table-peace_dividend_ptsd.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-peace_dividend_ptsd.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-peace_dividend_ptsd.qmd >}}


### Annual Savings from 1% Reduction in Refugee Support Costs {#sec-peace_dividend_refugee_support}

**Value**: $1.50B

Annual savings from 1% reduction in refugee support costs

$$
Cost_{ref,peace} = Cost_{ref,ann} \times Reduction_{treaty} = \$150.00B \times 1.0\% = \$1.50B
$$

**Methodology**: [../economics/peace-dividend](../economics/peace-dividend)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-peace_dividend_refugee_support.qmd >}}

{{< include ../figures/sensitivity-table-peace_dividend_refugee_support.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-peace_dividend_refugee_support.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-peace_dividend_refugee_support.qmd >}}


### Annual Savings from 1% Reduction in Trade Disruption {#sec-peace_dividend_trade_disruption}

**Value**: $6.16B

Annual savings from 1% reduction in trade disruption

$$
Savings_{trade,peace} = Disruption_{trade,ann} \times Reduction_{treaty} = \$616.00B \times 1.0\% = \$6.16B
$$

**Methodology**: [../economics/peace-dividend](../economics/peace-dividend)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-peace_dividend_trade_disruption.qmd >}}

{{< include ../figures/sensitivity-table-peace_dividend_trade_disruption.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-peace_dividend_trade_disruption.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-peace_dividend_trade_disruption.qmd >}}


### Annual Savings from 1% Reduction in Veteran Healthcare Costs {#sec-peace_dividend_veteran_healthcare}

**Value**: $2.00B

Annual savings from 1% reduction in veteran healthcare costs

$$
Cost_{vet,peace} = Cost_{vet,ann} \times Reduction_{treaty} = \$200.10B \times 1.0\% = \$2.00B
$$

**Methodology**: [../economics/peace-dividend](../economics/peace-dividend)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-peace_dividend_veteran_healthcare.qmd >}}

{{< include ../figures/sensitivity-table-peace_dividend_veteran_healthcare.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-peace_dividend_veteran_healthcare.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-peace_dividend_veteran_healthcare.qmd >}}


### Personal Lifetime Wealth (Age 30, 1% Treaty) {#sec-personal_lifetime_wealth}

**Value**: $508K

Personal lifetime wealth benefit for a 30-year-old with $50K income under 1% treaty. Life extension uncertainty (5-50 years) propagates through Monte Carlo to show full range of outcomes from conservative antibiotic precedent to optimistic aging reversal scenarios.

$$
\text{PLW} = \sum_{t=0}^{T + \Delta L} \frac{B_t}{(1+r)^t}
$$

**Methodology**: [../appendix/disease-eradication-personal-lifetime-wealth-calculations](../appendix/disease-eradication-personal-lifetime-wealth-calculations)

*~ Medium confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-personal_lifetime_wealth.qmd >}}

{{< include ../figures/sensitivity-table-personal_lifetime_wealth.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-personal_lifetime_wealth.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-personal_lifetime_wealth.qmd >}}


### US Per Capita Chronic Disease Cost {#sec-per_capita_chronic_disease_cost}

**Value**: $12.2K

US per capita chronic disease cost

$$
Cost_{percap,dis} = \frac{Spending_{chronic,ann}}{Population} = \frac{\$4.10T}{335M} = \$12.2K
$$

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-per_capita_chronic_disease_cost.qmd >}}

{{< include ../figures/sensitivity-table-per_capita_chronic_disease_cost.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-per_capita_chronic_disease_cost.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-per_capita_chronic_disease_cost.qmd >}}


### US Per Capita Mental Health Cost {#sec-per_capita_mental_health_cost}

**Value**: $1.04K

US per capita mental health cost

$$
Cost_{percap,health} = \frac{Cost_{mental,ann}}{Population} = \frac{\$350.00B}{335M} = \$1.0K
$$

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-per_capita_mental_health_cost.qmd >}}

{{< include ../figures/sensitivity-table-per_capita_mental_health_cost.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-per_capita_mental_health_cost.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-per_capita_mental_health_cost.qmd >}}


### Total Suffering Hours Eliminated {#sec-suffering_hours_eliminated_total}

**Value**: 7.65T hours

Total hours of human suffering eliminated by 8.2-year disease eradication timeline shift (one-time benefit from YLD component, not annual recurring)

$$
Hours = 868M \text{ (YLD)} \times 8{,}760 \text{ (hrs/yr)} = 7.60T
$$

**Methodology**: [../appendix/regulatory-mortality-analysis#daly-calculation](../appendix/regulatory-mortality-analysis#daly-calculation)

*~ Medium confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-suffering_hours_eliminated_total.qmd >}}

{{< include ../figures/sensitivity-table-suffering_hours_eliminated_total.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-suffering_hours_eliminated_total.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-suffering_hours_eliminated_total.qmd >}}


### Thalidomide DALYs Per Event {#sec-thalidomide_dalys_per_event}

**Value**: 41.8k DALYs

Total DALYs per US-scale thalidomide event (YLL + YLD)

$$
28{,}800 + 12{,}960 = 41{,}760 \text{ DALYs}
$$

*~ Medium confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-thalidomide_dalys_per_event.qmd >}}

{{< include ../figures/sensitivity-table-thalidomide_dalys_per_event.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-thalidomide_dalys_per_event.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-thalidomide_dalys_per_event.qmd >}}


### Thalidomide Deaths Per Event {#sec-thalidomide_deaths_per_event}

**Value**: 360 deaths

Deaths per US-scale thalidomide event

$$
900 \text{ (cases)} \times 40\% \text{ (mortality)} = 360 \text{ deaths}
$$

*~ Medium confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-thalidomide_deaths_per_event.qmd >}}

{{< include ../figures/sensitivity-table-thalidomide_deaths_per_event.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-thalidomide_deaths_per_event.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-thalidomide_deaths_per_event.qmd >}}


### Thalidomide Survivors Per Event {#sec-thalidomide_survivors_per_event}

**Value**: 540 cases

Survivors per US-scale thalidomide event

$$
900 \text{ (cases)} \times 60\% \text{ (survival)} = 540 \text{ survivors}
$$

*~ Medium confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-thalidomide_survivors_per_event.qmd >}}

{{< include ../figures/sensitivity-table-thalidomide_survivors_per_event.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-thalidomide_survivors_per_event.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-thalidomide_survivors_per_event.qmd >}}


### Thalidomide US Cases Prevented {#sec-thalidomide_us_cases_prevented}

**Value**: 900 cases

Estimated US thalidomide cases prevented by FDA rejection

$$
15{,}000 \times 6\% = 900 \text{ cases}
$$

*~ Medium confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-thalidomide_us_cases_prevented.qmd >}}

{{< include ../figures/sensitivity-table-thalidomide_us_cases_prevented.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-thalidomide_us_cases_prevented.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-thalidomide_us_cases_prevented.qmd >}}


### Thalidomide YLD Per Event {#sec-thalidomide_yld_per_event}

**Value**: 13.0k years

Years Lived with Disability per thalidomide event

$$
540 \text{ (surv)} \times 60 \text{ (yrs)} \times 0.4 \text{ (weight)} = 12{,}960 \text{ YLD}
$$

*~ Medium confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-thalidomide_yld_per_event.qmd >}}

{{< include ../figures/sensitivity-table-thalidomide_yld_per_event.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-thalidomide_yld_per_event.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-thalidomide_yld_per_event.qmd >}}


### Thalidomide YLL Per Event {#sec-thalidomide_yll_per_event}

**Value**: 28.8k years

Years of Life Lost per thalidomide event (infant deaths)

$$
360 \text{ (deaths)} \times 80 \text{ (years)} = 28{,}800 \text{ YLL}
$$

*~ Medium confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-thalidomide_yll_per_event.qmd >}}

{{< include ../figures/sensitivity-table-thalidomide_yll_per_event.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-thalidomide_yll_per_event.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-thalidomide_yll_per_event.qmd >}}


### Total Global Research Funding (Baseline + 1% treaty Funding) {#sec-total_research_funding_with_treaty}

**Value**: $94.7B

Total global research funding (baseline + 1% treaty funding)

$$
Funding_{total} = Spending_{global} + Funding_{ann} = \$67.50B + \$27.18B = \$94.68B
$$

**Methodology**: [../economics/economics](../economics/economics)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-total_research_funding_with_treaty.qmd >}}

{{< include ../figures/sensitivity-table-total_research_funding_with_treaty.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-total_research_funding_with_treaty.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-total_research_funding_with_treaty.qmd >}}


### Treaty System Benefit Multiplier vs Childhood Vaccination Programs {#sec-treaty_benefit_multiplier_vs_vaccines}

**Value**: 10.3 ratio

Treaty system benefit multiplier vs childhood vaccination programs

$$
Multiplier_{treaty} = \frac{Dividend_{ann}}{Benefit_{ann}} = \frac{\$155.05B}{\$15.00B} = 10.34
$$

**Methodology**: [../economics/economics#better-than-the-best-charities](../economics/economics#better-than-the-best-charities)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-treaty_benefit_multiplier_vs_vaccines.qmd >}}

{{< include ../figures/sensitivity-table-treaty_benefit_multiplier_vs_vaccines.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-treaty_benefit_multiplier_vs_vaccines.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-treaty_benefit_multiplier_vs_vaccines.qmd >}}


### Amortized Annual Treaty Campaign Cost {#sec-treaty_campaign_annual_cost_amortized}

**Value**: $250M

Amortized annual campaign cost (total cost ÷ campaign duration)

$$
AnnualCost = \$1B / 4 = \$0.25B
$$

**Methodology**: [../strategy/roadmap#campaign-budget](../strategy/roadmap#campaign-budget)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-treaty_campaign_annual_cost_amortized.qmd >}}

{{< include ../figures/sensitivity-table-treaty_campaign_annual_cost_amortized.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-treaty_campaign_annual_cost_amortized.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-treaty_campaign_annual_cost_amortized.qmd >}}


### Total 1% Treaty Campaign Cost {#sec-treaty_campaign_total_cost}

**Value**: $1.00B

Total treaty campaign cost (100% VICTORY Incentive Alignment Bonds)

$$
CampaignCost = \$300M \text{ (ref)} + \$650M \text{ (lob)} + \$50M \text{ (res)} = \$1.0B
$$

**Methodology**: [../appendix/fundraising-strategy#capital-structure-campaign-vs-implementation](../appendix/fundraising-strategy#capital-structure-campaign-vs-implementation)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-treaty_campaign_total_cost.qmd >}}

{{< include ../figures/sensitivity-table-treaty_campaign_total_cost.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-treaty_campaign_total_cost.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-treaty_campaign_total_cost.qmd >}}


### Target Voting Bloc Size for Campaign {#sec-treaty_campaign_voting_bloc_target}

**Value**: 280M of people

Target voting bloc size for campaign (3.5% of global population - critical mass for social change)

$$
Campaign_{camp,treaty} = Population_{global} \times Threshold_{global} = 8.00B \times 3.5\% = 280M
$$

**Methodology**: [../strategy/roadmap#voting-bloc](../strategy/roadmap#voting-bloc)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-treaty_campaign_voting_bloc_target.qmd >}}

{{< include ../figures/sensitivity-table-treaty_campaign_voting_bloc_target.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-treaty_campaign_voting_bloc_target.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-treaty_campaign_voting_bloc_target.qmd >}}


### Treaty ROI - Lag Elimination (PRIMARY) {#sec-treaty_complete_roi_all_benefits}

**Value**: 1.19M ratio

Treaty ROI based on eliminating the 8.2-year post-safety efficacy lag (PRIMARY METHODOLOGY). Total one-time benefit from disease eradication delay elimination divided by $1B campaign cost. This is the primary ROI estimate for total health benefits.

$$
ROI_{lag\_elimination} = \frac{\$1{,}286T}{\$1.00B} = 1{,}286{,}242:1
$$

**Methodology**: [../figures/dfda-investment-returns-bar-chart](../figures/dfda-investment-returns-bar-chart)

*~ Medium confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-treaty_complete_roi_all_benefits.qmd >}}

{{< include ../figures/sensitivity-table-treaty_complete_roi_all_benefits.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-treaty_complete_roi_all_benefits.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-treaty_complete_roi_all_benefits.qmd >}}


### Cost per DALY Averted (Timeline Shift) {#sec-treaty_dfda_cost_per_daly_timeline_shift}

**Value**: $0.126

Cost per DALY averted from one-time timeline shift (8.2 years). This is a conservative estimate that only counts campaign cost ($1B) and ignores all economic benefits ($27B/year funding unlocked + $50B/year R&D savings). For comparison: bed nets cost $89.0/DALY, deworming costs $4-10/DALY. This intervention is 700x more cost-effective than bed nets while also being self-funding.

$$
\text{Cost/DALY} = \frac{\$1.0B}{7.90B} = \$0.127
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis](../appendix/dfda-cost-benefit-analysis)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-treaty_dfda_cost_per_daly_timeline_shift.qmd >}}

{{< include ../figures/sensitivity-table-treaty_dfda_cost_per_daly_timeline_shift.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-treaty_dfda_cost_per_daly_timeline_shift.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-treaty_dfda_cost_per_daly_timeline_shift.qmd >}}


### Expected Cost per DALY (Risk-Adjusted) {#sec-treaty_expected_cost_per_daly}

**Value**: $13

Expected cost per DALY accounting for political success probability uncertainty. Monte Carlo samples from beta(0.1%, 10%) distribution. At the ultra-conservative 1% estimate, this is still more cost-effective than bed nets ($89.0/DALY).

$$
E[\text{Cost/DALY}] = \frac{\text{Cost}_{conditional}}{P_{success}}
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis](../appendix/dfda-cost-benefit-analysis)

*? Low confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-treaty_expected_cost_per_daly.qmd >}}

{{< include ../figures/sensitivity-table-treaty_expected_cost_per_daly.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-treaty_expected_cost_per_daly.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-treaty_expected_cost_per_daly.qmd >}}


### Expected Cost-Effectiveness vs Bed Nets Multiplier {#sec-treaty_expected_vs_bed_nets_multiplier}

**Value**: 7.07 ratio

Expected value multiplier vs bed nets (accounts for political uncertainty)

$$
E[\text{Multiplier}] = \frac{\$89}{\$0.51} = 175\times
$$

*? Low confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-treaty_expected_vs_bed_nets_multiplier.qmd >}}

{{< include ../figures/sensitivity-table-treaty_expected_vs_bed_nets_multiplier.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-treaty_expected_vs_bed_nets_multiplier.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-treaty_expected_vs_bed_nets_multiplier.qmd >}}


### Annual Lives Saved from 1% Reduction in Conflict Deaths {#sec-treaty_lives_saved_annual_global}

**Value**: 2.45k lives/year

Annual lives saved from 1% reduction in conflict deaths

$$
Deaths_{ann} = Deaths_{total} \times Reduction_{treaty} = 244{,}600 \times 1.0\% = 2{,}446
$$

**Methodology**: [../appendix/parameters-and-calculations#sec-treaty_lives_saved_annual_global](../appendix/parameters-and-calculations#sec-treaty_lives_saved_annual_global)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-treaty_lives_saved_annual_global.qmd >}}

{{< include ../figures/sensitivity-table-treaty_lives_saved_annual_global.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-treaty_lives_saved_annual_global.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-treaty_lives_saved_annual_global.qmd >}}


### 1% treaty Basic Annual Benefits (Peace + R&D Savings) {#sec-treaty_peace_plus_rd_annual_benefits}

**Value**: $155B

Basic annual benefits: peace dividend + dFDA R&D savings only (2 of 8 benefit categories, excludes regulatory delay value)

$$
Benefit_{ann} = Cost_{soc,ann} + Benefit_{gross,ann} = \$113.55B + \$41.50B = \$155.05B
$$

**Methodology**: [../appendix/parameters-and-calculations#sec-treaty_peace_plus_rd_annual_benefits](../appendix/parameters-and-calculations#sec-treaty_peace_plus_rd_annual_benefits)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-treaty_peace_plus_rd_annual_benefits.qmd >}}

{{< include ../figures/sensitivity-table-treaty_peace_plus_rd_annual_benefits.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-treaty_peace_plus_rd_annual_benefits.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-treaty_peace_plus_rd_annual_benefits.qmd >}}


### Annual QALYs Gained from Peace Dividend {#sec-treaty_qalys_gained_annual_global}

**Value**: 85.6k QALYs/year

Annual QALYs gained from peace dividend (lives saved × QALYs/life)

$$
Dividend_{ann} = QALYs_{RD} \times Deaths_{ann} = 35 \times 2{,}446 = 85{,}610
$$

**Methodology**: [../appendix/parameters-and-calculations#sec-treaty_qalys_gained_annual_global](../appendix/parameters-and-calculations#sec-treaty_qalys_gained_annual_global)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-treaty_qalys_gained_annual_global.qmd >}}

{{< include ../figures/sensitivity-table-treaty_qalys_gained_annual_global.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-treaty_qalys_gained_annual_global.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-treaty_qalys_gained_annual_global.qmd >}}


### 1% treaty Recurring Annual Benefits {#sec-treaty_recurring_benefits_annual}

**Value**: $155B

Truly recurring annual benefits from 1% treaty: peace dividend ($113.6B/year) + R&D savings ($41.5B/year). Note: Health benefits are one-time timeline shifts, NOT included here.

$$
Benefit_{ann} = Benefit_{DFDA,ann} + Cost_{soc,ann} = \$41.50B + \$113.55B = \$155.05B
$$

**Methodology**: [../economics/economics](../economics/economics)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-treaty_recurring_benefits_annual.qmd >}}

{{< include ../figures/sensitivity-table-treaty_recurring_benefits_annual.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-treaty_recurring_benefits_annual.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-treaty_recurring_benefits_annual.qmd >}}


### Treaty ROI - Historical Rate (Conservative Floor) {#sec-treaty_roi_historical_rate}

**Value**: 251k ratio

Treaty ROI based on historical rate of drug development (existing drugs only, conservative floor). Total one-time benefit from avoiding regulatory delay for drugs already in development divided by $1B campaign cost.

$$
ROI_{treaty} = \frac{Delay_{total}}{Cost_{camp,total}} = \frac{\$250.92T}{\$1.00B} = 250{,}920
$$

**Methodology**: [../figures/dfda-investment-returns-bar-chart](../figures/dfda-investment-returns-bar-chart)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-treaty_roi_historical_rate.qmd >}}

{{< include ../figures/sensitivity-table-treaty_roi_historical_rate.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-treaty_roi_historical_rate.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-treaty_roi_historical_rate.qmd >}}


### Treaty ROI - Innovation Acceleration (Optimistic) {#sec-treaty_roi_innovation_acceleration}

**Value**: 2.38M ratio

Treaty ROI based on lag elimination plus innovation acceleration effects (OPTIMISTIC UPPER BOUND). Includes cascading innovation effects from eliminating Phase 2-4 cost barriers. Research-backed 2× multiplier represents combined timeline and volume effects (Nature 2023, Woods et al. 2024).

$$
ROI_{treaty} = \frac{Ratio_{total}}{Cost_{camp,total}} = \frac{\$2382.84T}{\$1.00B} = 2.4M
$$

**Methodology**: [../figures/dfda-investment-returns-bar-chart](../figures/dfda-investment-returns-bar-chart)

*? Low confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-treaty_roi_innovation_acceleration.qmd >}}

{{< include ../figures/sensitivity-table-treaty_roi_innovation_acceleration.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-treaty_roi_innovation_acceleration.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-treaty_roi_innovation_acceleration.qmd >}}


### Treaty ROI - Lag Elimination (PRIMARY) {#sec-treaty_roi_lag_elimination}

**Value**: 1.19M ratio

Treaty ROI based on eliminating the 8.2-year post-safety efficacy lag (PRIMARY METHODOLOGY). Total one-time benefit from disease eradication delay elimination divided by $1B campaign cost. This is the primary ROI estimate for total health benefits.

$$
ROI_{lag\_elimination} = \frac{\$1{,}286T}{\$1.00B} = 1{,}286{,}242:1
$$

**Methodology**: [../figures/dfda-investment-returns-bar-chart](../figures/dfda-investment-returns-bar-chart)

*~ Medium confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-treaty_roi_lag_elimination.qmd >}}

{{< include ../figures/sensitivity-table-treaty_roi_lag_elimination.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-treaty_roi_lag_elimination.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-treaty_roi_lag_elimination.qmd >}}


### Total Annual Treaty System Costs {#sec-treaty_total_annual_costs}

**Value**: $290M

Total annual system costs (campaign + dFDA operations)

$$
Cost_{total} = Cost_{DFDA,ann} + Cost_{camp,ann} = \$40.0M + \$250.0M = \$290.0M
$$

**Methodology**: [../appendix/parameters-and-calculations#sec-treaty_total_annual_costs](../appendix/parameters-and-calculations#sec-treaty_total_annual_costs)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-treaty_total_annual_costs.qmd >}}

{{< include ../figures/sensitivity-table-treaty_total_annual_costs.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-treaty_total_annual_costs.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-treaty_total_annual_costs.qmd >}}


### 1% treaty Recurring Annual Benefits {#sec-treaty_total_complete_benefits_annual}

**Value**: $155B

Truly recurring annual benefits from 1% treaty: peace dividend ($113.6B/year) + R&D savings ($41.5B/year). Note: Health benefits are one-time timeline shifts, NOT included here.

$$
Benefit_{total} = Benefit_{DFDA,ann} + Cost_{soc,ann} = \$41.50B + \$113.55B = \$155.05B
$$

**Methodology**: [../economics/economics](../economics/economics)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-treaty_total_complete_benefits_annual.qmd >}}

{{< include ../figures/sensitivity-table-treaty_total_complete_benefits_annual.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-treaty_total_complete_benefits_annual.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-treaty_total_complete_benefits_annual.qmd >}}


### Cost-Effectiveness vs Bed Nets Multiplier {#sec-treaty_vs_bed_nets_multiplier}

**Value**: 707 ratio

How many times more cost-effective than bed nets (using $89/DALY midpoint estimate)

$$
\text{Multiplier} = \frac{\$89}{\$0.127} = 701\times
$$

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-treaty_vs_bed_nets_multiplier.qmd >}}

{{< include ../figures/sensitivity-table-treaty_vs_bed_nets_multiplier.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-treaty_vs_bed_nets_multiplier.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-treaty_vs_bed_nets_multiplier.qmd >}}


### Cumulative Trial Capacity Years Over 20 Years {#sec-trial_capacity_cumulative_years_20yr}

**Value**: 456 years

Cumulative trial-capacity-equivalent years over 20-year period

$$
Capacity_{20yr} = 25.7 \times 20 = 514 \text{ years}
$$

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-trial_capacity_cumulative_years_20yr.qmd >}}

{{< include ../figures/sensitivity-table-trial_capacity_cumulative_years_20yr.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-trial_capacity_cumulative_years_20yr.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-trial_capacity_cumulative_years_20yr.qmd >}}


### Trial Capacity Multiplier {#sec-trial_capacity_multiplier}

**Value**: 22.8 ratio

Trial capacity multiplier from DIH funding capacity vs. current global trial participation

$$
Multiplier = \frac{Fundable_{ann}}{Trials_{curr}} = \frac{43.4M}{1.9M} = 22.85
$$

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-trial_capacity_multiplier.qmd >}}

{{< include ../figures/sensitivity-table-trial_capacity_multiplier.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-trial_capacity_multiplier.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-trial_capacity_multiplier.qmd >}}


### Ratio of Type Ii Error Cost to Type I Error Benefit {#sec-type_ii_error_cost_ratio}

**Value**: 3.07k ratio

Ratio of Type II error cost to Type I error benefit (harm from delay vs. harm prevented)

$$
Cost = \frac{DALYs_{dis}}{DALYs} = \frac{7.94B}{2.6M} = 3{,}068
$$

**Methodology**: [../appendix/regulatory-mortality-analysis#risk-analysis](../appendix/regulatory-mortality-analysis#risk-analysis)

*~ Medium confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-type_ii_error_cost_ratio.qmd >}}

{{< include ../figures/sensitivity-table-type_ii_error_cost_ratio.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-type_ii_error_cost_ratio.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-type_ii_error_cost_ratio.qmd >}}


### Maximum DALYs Saved by FDA Preventing Unsafe Drugs (1962-2024) {#sec-type_i_error_benefit_dalys}

**Value**: 2.59M DALYs

Maximum DALYs saved by FDA preventing unsafe drugs over 62-year period 1962-2024 (extreme overestimate: one Thalidomide-scale event per year)

$$
41{,}760 \times 62 = 2.59M \text{ DALYs}
$$

**Methodology**: [../appendix/regulatory-mortality-analysis#risk-analysis](../appendix/regulatory-mortality-analysis#risk-analysis)

*? Low confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-type_i_error_benefit_dalys.qmd >}}

{{< include ../figures/sensitivity-table-type_i_error_benefit_dalys.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-type_i_error_benefit_dalys.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-type_i_error_benefit_dalys.qmd >}}


### US Major Diseases Total Annual Cost {#sec-us_major_diseases_total_annual_cost}

**Value**: $1.25T

Total annual US cost of major diseases (diabetes, Alzheimer's, heart disease, cancer)

$$
Cost_{total} = Cost_{alz,ann} + Cost_{cancer,ann} + Cost_{diab,ann} + Cost_{heart,ann} = \$355.00B + \$208.00B + \$327.00B + \$363.00B = \$1.25T
$$

**Methodology**: [../solution/aligning-incentives#insurance-companies](../solution/aligning-incentives#insurance-companies)

*✓ High confidence*

#### Sensitivity Analysis

{{< include ../figures/tornado-us_major_diseases_total_annual_cost.qmd >}}

{{< include ../figures/sensitivity-table-us_major_diseases_total_annual_cost.qmd >}}

#### Monte Carlo Distribution

{{< include ../figures/mc-distribution-us_major_diseases_total_annual_cost.qmd >}}

#### Exceedance Probability

{{< include ../figures/exceedance-us_major_diseases_total_annual_cost.qmd >}}


## External Data Sources {#sec-external}

Parameters sourced from peer-reviewed publications, institutional databases, and authoritative reports.

### Antidepressant Trial Exclusion Rate {#sec-antidepressant_trial_exclusion_rate}

**Value**: 86.1%

Mean exclusion rate in antidepressant trials (86.1% of real-world patients excluded)

**Source**: [antidepressant-trial-exclusion-rates](../references.qmd#antidepressant-trial-exclusion-rates)

*✓ High confidence*


### Average Annual Stock Market Return {#sec-average_market_return_pct}

**Value**: 10%

Average annual stock market return (10%)

**Source**: [warren-buffett-career-average-return-20-pct](../references.qmd#warren-buffett-career-average-return-20-pct)

*✓ High confidence*


### Average US Hourly Wage {#sec-average_us_hourly_wage}

**Value**: $30

Average US hourly wage

**Source**: [average-us-hourly-wage](../references.qmd#average-us-hourly-wage)

*✓ High confidence*


### Baseline Annual Lives Saved by Pharmaceuticals {#sec-baseline_lives_saved_annual}

**Value**: 12 deaths/year

Baseline annual lives saved by pharmaceuticals (conservative aggregate)

**Source**: [who-global-health-estimates-2024](../references.qmd#who-global-health-estimates-2024)

*~ Medium confidence • 📊 Peer-reviewed • Updated 2024*


### Bed Nets Cost per DALY {#sec-bed_nets_cost_per_daly}

**Value**: $89

GiveWell cost per DALY for bed nets (midpoint estimate, range $78-100)

**Source**: [givewell-cost-per-life-saved](../references.qmd#givewell-cost-per-life-saved)

#### Uncertainty Range

**Technical**: 95% CI: [$78, $100] • Distribution: Normal

**What this means**: This estimate has moderate uncertainty. The true value likely falls between $78 and $100 (±12%). This represents a reasonable range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The normal distribution means values cluster around the center with equal chances of being higher or lower.*

#### Input Distribution

{{< include ../figures/distribution-bed_nets_cost_per_daly.qmd >}}

*✓ High confidence*


### Average Reading Speed {#sec-book_reading_speed_wpm}

**Value**: 200 words/minute

Average reading speed (conservative for non-fiction)

**Source**: [average-reading-speed](../references.qmd#average-reading-speed)

*✓ High confidence*


### Total Annual Value of Unpaid Caregiving in US {#sec-caregiver_annual_value_total}

**Value**: $600B

Total annual value of unpaid caregiving in US

**Source**: [unpaid-caregiver-hours-economic-value](../references.qmd#unpaid-caregiver-hours-economic-value)

*✓ High confidence*


### Number of Unpaid Caregivers in US {#sec-caregiver_count_us}

**Value**: 38.0M people

Number of unpaid caregivers in US

**Source**: [unpaid-caregiver-hours-economic-value](../references.qmd#unpaid-caregiver-hours-economic-value)

*✓ High confidence*


### Average Monthly Hours of Unpaid Family Caregiving in US {#sec-caregiver_hours_per_month}

**Value**: 20 hours/month

Average monthly hours of unpaid family caregiving in US

**Source**: [unpaid-caregiver-hours-economic-value](../references.qmd#unpaid-caregiver-hours-economic-value)

*✓ High confidence*


### Estimated Replacement Cost per Hour of Caregiving {#sec-caregiver_value_per_hour_simple}

**Value**: $25

Estimated replacement cost per hour of caregiving

**Source**: [unpaid-caregiver-hours-economic-value](../references.qmd#unpaid-caregiver-hours-economic-value)

*✓ High confidence*


### Estimated Annual Global Economic Benefit from Childhood Vaccination Programs {#sec-childhood_vaccination_annual_benefit}

**Value**: $15B

Estimated annual global economic benefit from childhood vaccination programs (measles, polio, etc.)

**Source**: [childhood-vaccination-economic-benefits](../references.qmd#childhood-vaccination-economic-benefits)

#### Uncertainty Range

**Technical**: Distribution: Lognormal (SE: $4.50B)

#### Input Distribution

{{< include ../figures/distribution-childhood_vaccination_annual_benefit.qmd >}}

*✓ High confidence*


### Return on Investment from Childhood Vaccination Programs {#sec-childhood_vaccination_roi}

**Value**: 13 ratio

Return on investment from childhood vaccination programs

**Source**: [childhood-vaccination-roi](../references.qmd#childhood-vaccination-roi)

*✓ High confidence*


### Disability Weight for Untreated Chronic Conditions {#sec-chronic_disease_disability_weight}

**Value**: 0.35 weight

Disability weight for untreated chronic conditions (WHO Global Burden of Disease)

**Source**: [who-global-health-estimates-2024](../references.qmd#who-global-health-estimates-2024)

#### Uncertainty Range

**Technical**: Distribution: Normal (SE: 0.07 weight)

#### Input Distribution

{{< include ../figures/distribution-chronic_disease_disability_weight.qmd >}}

*~ Medium confidence • 📊 Peer-reviewed*


### Current Active Trials at Any Given Time {#sec-current_active_trials}

**Value**: 10.0k trials

Current active trials at any given time (3-5 year duration)

**Source**: [clinicaltrials-gov-enrollment-data-2025](../references.qmd#clinicaltrials-gov-enrollment-data-2025)

*✓ High confidence*


### Current Clinical Trial Participation Rate {#sec-current_clinical_trial_participation_rate}

**Value**: 0.06%

Current clinical trial participation rate (0.06% of population)

**Source**: [clinical-trial-patient-participation-rate](../references.qmd#clinical-trial-patient-participation-rate)

*✓ High confidence*


### Global Population with Chronic Diseases {#sec-current_disease_patients_global}

**Value**: 2.40B people

Global population with chronic diseases

**Source**: [disease-prevalence-2-billion](../references.qmd#disease-prevalence-2-billion)

#### Uncertainty Range

**Technical**: 95% CI: [2.00B people, 2.80B people] • Distribution: Lognormal

**What this means**: This estimate has moderate uncertainty. The true value likely falls between 2.00B people and 2.80B people (±17%). This represents a reasonable range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

#### Input Distribution

{{< include ../figures/distribution-current_disease_patients_global.qmd >}}

*✓ High confidence*


### Average Annual New Drug Approvals Globally {#sec-current_drug_approvals_per_year}

**Value**: 50 drugs/year

Average annual new drug approvals globally

**Source**: [global-new-drug-approvals-50-annually](../references.qmd#global-new-drug-approvals-50-annually)

*✓ High confidence*


### Current Global Clinical Trials per Year {#sec-current_trials_per_year}

**Value**: 3.30k trials/year

Current global clinical trials per year

**Source**: [global-clinical-trials-market-2024](../references.qmd#global-clinical-trials-market-2024)

#### Uncertainty Range

**Technical**: 95% CI: [2.64k trials/year, 3.96k trials/year] • Distribution: Lognormal

**What this means**: This estimate has moderate uncertainty. The true value likely falls between 2.64k trials/year and 3.96k trials/year (±20%). This represents a reasonable range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

#### Input Distribution

{{< include ../figures/distribution-current_trials_per_year.qmd >}}

*✓ High confidence*


### Current Trial Abandonment Rate {#sec-current_trial_abandonment_rate}

**Value**: 40%

Current trial abandonment rate (40% never complete)

**Source**: [clinical-trial-abandonment-rate](../references.qmd#clinical-trial-abandonment-rate)

*✓ High confidence*


### Annual Global Clinical Trial Participants {#sec-current_trial_slots_available}

**Value**: 1.90M patients/year

Annual global clinical trial participants (IQVIA 2022: 1.9M post-COVID normalization)

**Source**: [global-trial-participant-capacity](../references.qmd#global-trial-participant-capacity)

#### Uncertainty Range

**Technical**: 95% CI: [1.50M patients/year, 2.30M patients/year] • Distribution: Lognormal

**What this means**: This estimate has moderate uncertainty. The true value likely falls between 1.50M patients/year and 2.30M patients/year (±21%). This represents a reasonable range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

#### Input Distribution

{{< include ../figures/distribution-current_trial_slots_available.qmd >}}

*✓ High confidence*


### Annual Defense Industry Lobbying Spending {#sec-defense_lobbying_annual}

**Value**: $127M

Annual defense industry lobbying spending

**Source**: [lobbying-spend-defense](../references.qmd#lobbying-spend-defense)

*✓ High confidence • 📊 Peer-reviewed • Updated 2024*


### Deworming Cost per DALY {#sec-deworming_cost_per_daly}

**Value**: $55

Cost per DALY for deworming programs (range $28-82, midpoint estimate). GiveWell notes this 2011 estimate is outdated and their current methodology focuses on long-term income effects rather than short-term health DALYs.

**Source**: [deworming-cost-per-daly](../references.qmd#deworming-cost-per-daly)

*? Low confidence*


### Drug Development Cost (1980s) {#sec-drug_development_cost_1980s}

**Value**: $194M

Drug development cost in 1980s (compounded to approval, 1990 dollars)

**Source**: [pre-1962-drug-costs-timeline](../references.qmd#pre-1962-drug-costs-timeline)

#### Uncertainty Range

**Technical**: Distribution: Fixed

#### Input Distribution

{{< include ../figures/distribution-drug_development_cost_1980s.qmd >}}

*✓ High confidence*


### Economic Multiplier for Education Investment {#sec-economic_multiplier_education_investment}

**Value**: 2.1 ratio

Economic multiplier for education investment (2.1x ROI)

**Source**: [education-investment-economic-multiplier](../references.qmd#education-investment-economic-multiplier)

*✓ High confidence*


### Economic Multiplier for Healthcare Investment {#sec-economic_multiplier_healthcare_investment}

**Value**: 4.3 ratio

Economic multiplier for healthcare investment (4.3x ROI)

**Source**: [healthcare-investment-economic-multiplier](../references.qmd#healthcare-investment-economic-multiplier)

*✓ High confidence*


### Economic Multiplier for Infrastructure Investment {#sec-economic_multiplier_infrastructure_investment}

**Value**: 1.6 ratio

Economic multiplier for infrastructure investment (1.6x ROI)

**Source**: [infrastructure-investment-economic-multiplier](../references.qmd#infrastructure-investment-economic-multiplier)

*✓ High confidence*


### Economic Multiplier for Military Spending {#sec-economic_multiplier_military_spending}

**Value**: 0.6 ratio

Economic multiplier for military spending (0.6x ROI)

**Source**: [military-spending-economic-multiplier](../references.qmd#military-spending-economic-multiplier)

*✓ High confidence*


### Regulatory Delay for Efficacy Testing Post-Safety Verification {#sec-efficacy_lag_years}

**Value**: 8.2 years

Regulatory delay for efficacy testing (Phase II/III) post-safety verification

**Source**: [bio-clinical-development-2021](../references.qmd#bio-clinical-development-2021)

#### Uncertainty Range

**Technical**: Distribution: Normal (SE: 1 years)

#### Input Distribution

{{< include ../figures/distribution-efficacy_lag_years.qmd >}}

*✓ High confidence • 📊 Peer-reviewed • Updated 2021*


### FDA Phase 1 to Approval Timeline {#sec-fda_phase_1_to_approval_years}

**Value**: 9.1 years

FDA timeline from Phase 1 start to approval (Phase 1-3 + NDA review)

**Source**: [fda-approval-timeline-10-years](../references.qmd#fda-approval-timeline-10-years)

#### Uncertainty Range

**Technical**: 95% CI: [6 years, 12 years] • Distribution: Gamma (SE: 2 years)

**What this means**: There's significant uncertainty here. The true value likely falls between 6 years and 12 years (±33%). This represents a wide range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The gamma distribution means values follow a specific statistical pattern.*

#### Input Distribution

{{< include ../figures/distribution-fda_phase_1_to_approval_years.qmd >}}

*✓ High confidence*


### Givewell Average Cost per Life Saved Across Top Charities {#sec-givewell_cost_per_life_avg}

**Value**: $4.50K

GiveWell average cost per life saved across top charities

**Source**: [givewell-cost-per-life-saved](../references.qmd#givewell-cost-per-life-saved)

*✓ High confidence*


### Givewell Cost per Life Saved (Maximum) {#sec-givewell_cost_per_life_max}

**Value**: $5.50K

GiveWell cost per life saved (Against Malaria Foundation)

**Source**: [givewell-cost-per-life-saved](../references.qmd#givewell-cost-per-life-saved)

*✓ High confidence*


### Givewell Cost per Life Saved (Minimum) {#sec-givewell_cost_per_life_min}

**Value**: $3.50K

GiveWell cost per life saved (Helen Keller International)

**Source**: [givewell-cost-per-life-saved](../references.qmd#givewell-cost-per-life-saved)

*✓ High confidence*


### Annual Deaths from Active Combat Worldwide {#sec-global_annual_conflict_deaths_active_combat}

**Value**: 234k deaths/year

Annual deaths from active combat worldwide

**Source**: [acled-active-combat-deaths](../references.qmd#acled-active-combat-deaths)

#### Uncertainty Range

**Technical**: 95% CI: [180k deaths/year, 300k deaths/year] • Distribution: Lognormal

**What this means**: There's significant uncertainty here. The true value likely falls between 180k deaths/year and 300k deaths/year (±26%). This represents a wide range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

#### Input Distribution

{{< include ../figures/distribution-global_annual_conflict_deaths_active_combat.qmd >}}

*✓ High confidence*


### Annual Deaths from State Violence {#sec-global_annual_conflict_deaths_state_violence}

**Value**: 2.70k deaths/year

Annual deaths from state violence

**Source**: [ucdp-state-violence-deaths](../references.qmd#ucdp-state-violence-deaths)

#### Uncertainty Range

**Technical**: 95% CI: [1.50k deaths/year, 5.00k deaths/year] • Distribution: Lognormal

**What this means**: This estimate is highly uncertain. The true value likely falls between 1.50k deaths/year and 5.00k deaths/year (±65%). This represents a very wide range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

#### Input Distribution

{{< include ../figures/distribution-global_annual_conflict_deaths_state_violence.qmd >}}

*✓ High confidence*


### Annual Deaths from Terror Attacks Globally {#sec-global_annual_conflict_deaths_terror_attacks}

**Value**: 8.30k deaths/year

Annual deaths from terror attacks globally

**Source**: [gtd-terror-attack-deaths](../references.qmd#gtd-terror-attack-deaths)

#### Uncertainty Range

**Technical**: 95% CI: [6.00k deaths/year, 12.0k deaths/year] • Distribution: Lognormal

**What this means**: There's significant uncertainty here. The true value likely falls between 6.00k deaths/year and 12.0k deaths/year (±36%). This represents a wide range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

#### Input Distribution

{{< include ../figures/distribution-global_annual_conflict_deaths_terror_attacks.qmd >}}

*✓ High confidence*


### Annual Deaths from Curable Diseases Globally {#sec-global_annual_deaths_curable_diseases}

**Value**: 55.0M deaths/year

Annual deaths from all diseases and aging globally

**Source**: [who-global-health-estimates-2024](../references.qmd#who-global-health-estimates-2024)

*✓ High confidence*


### Annual Environmental Damage and Restoration Costs from Conflict {#sec-global_annual_environmental_damage_conflict}

**Value**: $100B

Annual environmental damage and restoration costs from conflict

**Source**: [environmental-cost-of-war](../references.qmd#environmental-cost-of-war)

#### Uncertainty Range

**Technical**: 95% CI: [$70B, $140B] • Distribution: Lognormal

**What this means**: There's significant uncertainty here. The true value likely falls between $70B and $140B (±35%). This represents a wide range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

#### Input Distribution

{{< include ../figures/distribution-global_annual_environmental_damage_conflict.qmd >}}

*✓ High confidence*


### Annual Infrastructure Damage to Communications from Conflict {#sec-global_annual_infrastructure_damage_communications_conflict}

**Value**: $298B

Annual infrastructure damage to communications from conflict

**Source**: [environmental-cost-of-war](../references.qmd#environmental-cost-of-war)

#### Uncertainty Range

**Technical**: 95% CI: [$209B, $418B] • Distribution: Lognormal

**What this means**: There's significant uncertainty here. The true value likely falls between $209B and $418B (±35%). This represents a wide range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

#### Input Distribution

{{< include ../figures/distribution-global_annual_infrastructure_damage_communications_conflict.qmd >}}

*✓ High confidence*


### Annual Infrastructure Damage to Education Facilities from Conflict {#sec-global_annual_infrastructure_damage_education_conflict}

**Value**: $234B

Annual infrastructure damage to education facilities from conflict

**Source**: [environmental-cost-of-war](../references.qmd#environmental-cost-of-war)

#### Uncertainty Range

**Technical**: 95% CI: [$164B, $328B] • Distribution: Lognormal

**What this means**: There's significant uncertainty here. The true value likely falls between $164B and $328B (±35%). This represents a wide range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

#### Input Distribution

{{< include ../figures/distribution-global_annual_infrastructure_damage_education_conflict.qmd >}}

*✓ High confidence*


### Annual Infrastructure Damage to Energy Systems from Conflict {#sec-global_annual_infrastructure_damage_energy_conflict}

**Value**: $422B

Annual infrastructure damage to energy systems from conflict

**Source**: [environmental-cost-of-war](../references.qmd#environmental-cost-of-war)

#### Uncertainty Range

**Technical**: 95% CI: [$295B, $590B] • Distribution: Lognormal

**What this means**: There's significant uncertainty here. The true value likely falls between $295B and $590B (±35%). This represents a wide range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

#### Input Distribution

{{< include ../figures/distribution-global_annual_infrastructure_damage_energy_conflict.qmd >}}

*✓ High confidence*


### Annual Infrastructure Damage to Healthcare Facilities from Conflict {#sec-global_annual_infrastructure_damage_healthcare_conflict}

**Value**: $166B

Annual infrastructure damage to healthcare facilities from conflict

**Source**: [environmental-cost-of-war](../references.qmd#environmental-cost-of-war)

#### Uncertainty Range

**Technical**: 95% CI: [$116B, $232B] • Distribution: Lognormal

**What this means**: There's significant uncertainty here. The true value likely falls between $116B and $232B (±35%). This represents a wide range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

#### Input Distribution

{{< include ../figures/distribution-global_annual_infrastructure_damage_healthcare_conflict.qmd >}}

*✓ High confidence*


### Annual Infrastructure Damage to Transportation from Conflict {#sec-global_annual_infrastructure_damage_transportation_conflict}

**Value**: $487B

Annual infrastructure damage to transportation from conflict

**Source**: [environmental-cost-of-war](../references.qmd#environmental-cost-of-war)

#### Uncertainty Range

**Technical**: 95% CI: [$340B, $680B] • Distribution: Lognormal

**What this means**: There's significant uncertainty here. The true value likely falls between $340B and $680B (±35%). This represents a wide range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

#### Input Distribution

{{< include ../figures/distribution-global_annual_infrastructure_damage_transportation_conflict.qmd >}}

*✓ High confidence*


### Annual Infrastructure Damage to Water Systems from Conflict {#sec-global_annual_infrastructure_damage_water_conflict}

**Value**: $268B

Annual infrastructure damage to water systems from conflict

**Source**: [environmental-cost-of-war](../references.qmd#environmental-cost-of-war)

#### Uncertainty Range

**Technical**: 95% CI: [$187B, $375B] • Distribution: Lognormal

**What this means**: There's significant uncertainty here. The true value likely falls between $187B and $375B (±35%). This represents a wide range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

#### Input Distribution

{{< include ../figures/distribution-global_annual_infrastructure_damage_water_conflict.qmd >}}

*✓ High confidence*


### Annual Lives Saved by Medical Research Globally {#sec-global_annual_lives_saved_by_med_research}

**Value**: 4.20M lives/year

Annual lives saved by medical research globally

**Source**: [medical-research-lives-saved-annually](../references.qmd#medical-research-lives-saved-annually)

#### Uncertainty Range

**Technical**: 95% CI: [3.00M lives/year, 6.00M lives/year] • Distribution: Lognormal

**What this means**: There's significant uncertainty here. The true value likely falls between 3.00M lives/year and 6.00M lives/year (±36%). This represents a wide range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

#### Input Distribution

{{< include ../figures/distribution-global_annual_lives_saved_by_med_research.qmd >}}

*✓ High confidence*


### Annual Lost Economic Growth from Military Spending Opportunity Cost {#sec-global_annual_lost_economic_growth_military_spending}

**Value**: $2.72T

Annual lost economic growth from military spending opportunity cost

**Source**: [disparity-ratio-weapons-vs-cures](../references.qmd#disparity-ratio-weapons-vs-cures)

#### Uncertainty Range

**Technical**: 95% CI: [$1.90T, $3.80T] • Distribution: Lognormal

**What this means**: There's significant uncertainty here. The true value likely falls between $1.90T and $3.80T (±35%). This represents a wide range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

#### Input Distribution

{{< include ../figures/distribution-global_annual_lost_economic_growth_military_spending.qmd >}}

*✓ High confidence*


### Annual Lost Productivity from Conflict Casualties {#sec-global_annual_lost_human_capital_conflict}

**Value**: $300B

Annual lost productivity from conflict casualties

**Source**: [lost-human-capital-war-cost](../references.qmd#lost-human-capital-war-cost)

#### Uncertainty Range

**Technical**: 95% CI: [$210B, $420B] • Distribution: Lognormal

**What this means**: There's significant uncertainty here. The true value likely falls between $210B and $420B (±35%). This represents a wide range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

#### Input Distribution

{{< include ../figures/distribution-global_annual_lost_human_capital_conflict.qmd >}}

*✓ High confidence*


### Annual PTSD and Mental Health Costs from Conflict {#sec-global_annual_psychological_impact_costs_conflict}

**Value**: $232B

Annual PTSD and mental health costs from conflict

**Source**: [psychological-impact-war-cost](../references.qmd#psychological-impact-war-cost)

#### Uncertainty Range

**Technical**: 95% CI: [$162B, $325B] • Distribution: Lognormal

**What this means**: There's significant uncertainty here. The true value likely falls between $162B and $325B (±35%). This represents a wide range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

#### Input Distribution

{{< include ../figures/distribution-global_annual_psychological_impact_costs_conflict.qmd >}}

*✓ High confidence*


### Annual Refugee Support Costs {#sec-global_annual_refugee_support_costs}

**Value**: $150B

Annual refugee support costs (108.4M refugees × $1,384/year)

**Source**: [unhcr-refugee-support-cost](../references.qmd#unhcr-refugee-support-cost)

#### Uncertainty Range

**Technical**: 95% CI: [$105B, $210B] • Distribution: Lognormal

**What this means**: There's significant uncertainty here. The true value likely falls between $105B and $210B (±35%). This represents a wide range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

#### Input Distribution

{{< include ../figures/distribution-global_annual_refugee_support_costs.qmd >}}

*✓ High confidence*


### Annual Trade Disruption Costs from Currency Instability {#sec-global_annual_trade_disruption_currency_conflict}

**Value**: $57.4B

Annual trade disruption costs from currency instability

**Source**: [world-bank-trade-disruption-conflict](../references.qmd#world-bank-trade-disruption-conflict)

#### Uncertainty Range

**Technical**: 95% CI: [$40B, $80B] • Distribution: Lognormal

**What this means**: There's significant uncertainty here. The true value likely falls between $40B and $80B (±35%). This represents a wide range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

#### Input Distribution

{{< include ../figures/distribution-global_annual_trade_disruption_currency_conflict.qmd >}}

*✓ High confidence*


### Annual Trade Disruption Costs from Energy Price Volatility {#sec-global_annual_trade_disruption_energy_price_conflict}

**Value**: $125B

Annual trade disruption costs from energy price volatility

**Source**: [world-bank-trade-disruption-conflict](../references.qmd#world-bank-trade-disruption-conflict)

#### Uncertainty Range

**Technical**: 95% CI: [$87B, $175B] • Distribution: Lognormal

**What this means**: There's significant uncertainty here. The true value likely falls between $87B and $175B (±35%). This represents a wide range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

#### Input Distribution

{{< include ../figures/distribution-global_annual_trade_disruption_energy_price_conflict.qmd >}}

*✓ High confidence*


### Annual Trade Disruption Costs from Shipping Disruptions {#sec-global_annual_trade_disruption_shipping_conflict}

**Value**: $247B

Annual trade disruption costs from shipping disruptions

**Source**: [world-bank-trade-disruption-conflict](../references.qmd#world-bank-trade-disruption-conflict)

#### Uncertainty Range

**Technical**: 95% CI: [$173B, $346B] • Distribution: Lognormal

**What this means**: There's significant uncertainty here. The true value likely falls between $173B and $346B (±35%). This represents a wide range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

#### Input Distribution

{{< include ../figures/distribution-global_annual_trade_disruption_shipping_conflict.qmd >}}

*✓ High confidence*


### Annual Trade Disruption Costs from Supply Chain Disruptions {#sec-global_annual_trade_disruption_supply_chain_conflict}

**Value**: $187B

Annual trade disruption costs from supply chain disruptions

**Source**: [world-bank-trade-disruption-conflict](../references.qmd#world-bank-trade-disruption-conflict)

#### Uncertainty Range

**Technical**: 95% CI: [$131B, $262B] • Distribution: Lognormal

**What this means**: There's significant uncertainty here. The true value likely falls between $131B and $262B (±35%). This represents a wide range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

#### Input Distribution

{{< include ../figures/distribution-global_annual_trade_disruption_supply_chain_conflict.qmd >}}

*✓ High confidence*


### Annual Veteran Healthcare Costs {#sec-global_annual_veteran_healthcare_costs}

**Value**: $200B

Annual veteran healthcare costs (20-year projected)

**Source**: [veteran-healthcare-cost-projections](../references.qmd#veteran-healthcare-cost-projections)

#### Uncertainty Range

**Technical**: 95% CI: [$140B, $280B] • Distribution: Lognormal

**What this means**: There's significant uncertainty here. The true value likely falls between $140B and $280B (±35%). This represents a wide range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

#### Input Distribution

{{< include ../figures/distribution-global_annual_veteran_healthcare_costs.qmd >}}

*✓ High confidence*


### Annual Global Spending on Clinical Trials {#sec-global_clinical_trials_spending_annual}

**Value**: $83B

Annual global spending on clinical trials (Total: Government + Industry)

**Source**: [global-clinical-trials-market-2024](../references.qmd#global-clinical-trials-market-2024)

#### Uncertainty Range

**Technical**: 95% CI: [$60B, $110B] • Distribution: Lognormal (SE: $12.5B)

**What this means**: There's significant uncertainty here. The true value likely falls between $60B and $110B (±30%). This represents a wide range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

#### Input Distribution

{{< include ../figures/distribution-global_clinical_trials_spending_annual.qmd >}}

*✓ High confidence*


### Daily Deaths from Curable Diseases Globally {#sec-global_daily_deaths_curable_diseases}

**Value**: 150k deaths/day

Daily deaths from all diseases and aging globally

**Source**: [who-daily-deaths](../references.qmd#who-daily-deaths)

#### Uncertainty Range

**Technical**: 95% CI: [120k deaths/day, 180k deaths/day] • Distribution: Lognormal

**What this means**: This estimate has moderate uncertainty. The true value likely falls between 120k deaths/day and 180k deaths/day (±20%). This represents a reasonable range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

#### Input Distribution

{{< include ../figures/distribution-global_daily_deaths_curable_diseases.qmd >}}

*✓ High confidence*


### Global Daily Deaths from Disease and Aging {#sec-global_disease_deaths_daily}

**Value**: 150k deaths/day

Total global deaths per day from all disease and aging (WHO Global Burden of Disease 2024)

**Source**: [who-global-health-estimates-2024](../references.qmd#who-global-health-estimates-2024)

#### Uncertainty Range

**Technical**: Distribution: Normal (SE: 7.50k deaths/day)

#### Input Distribution

{{< include ../figures/distribution-global_disease_deaths_daily.qmd >}}

*✓ High confidence • 📊 Peer-reviewed*


### Global Annual Direct Medical Costs of Disease {#sec-global_disease_direct_medical_cost_annual}

**Value**: $9.90T

Direct medical costs of disease globally (treatment, hospitalization, medication)

**Source**: [disease-economic-burden-109t](../references.qmd#disease-economic-burden-109t)

#### Uncertainty Range

**Technical**: 95% CI: [$7.00T, $14T] • Distribution: Lognormal

**What this means**: There's significant uncertainty here. The true value likely falls between $7.00T and $14T (±35%). This represents a wide range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

#### Input Distribution

{{< include ../figures/distribution-global_disease_direct_medical_cost_annual.qmd >}}

*✓ High confidence*


### Global Annual Economic Value of Human Life Lost to Disease {#sec-global_disease_human_life_value_loss_annual}

**Value**: $94.2T

Economic value of human life lost to disease annually (mortality valuation)

**Source**: [disease-economic-burden-109t](../references.qmd#disease-economic-burden-109t)

#### Uncertainty Range

**Technical**: 95% CI: [$66T, $132T] • Distribution: Lognormal

**What this means**: There's significant uncertainty here. The true value likely falls between $66T and $132T (±35%). This represents a wide range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

#### Input Distribution

{{< include ../figures/distribution-global_disease_human_life_value_loss_annual.qmd >}}

*✓ High confidence*


### Global Annual Productivity Loss from Disease {#sec-global_disease_productivity_loss_annual}

**Value**: $5.00T

Annual productivity loss from disease globally (absenteeism, reduced output)

**Source**: [disease-economic-burden-109t](../references.qmd#disease-economic-burden-109t)

#### Uncertainty Range

**Technical**: 95% CI: [$3.50T, $7.00T] • Distribution: Lognormal

**What this means**: There's significant uncertainty here. The true value likely falls between $3.50T and $7.00T (±35%). This represents a wide range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

#### Input Distribution

{{< include ../figures/distribution-global_disease_productivity_loss_annual.qmd >}}

*✓ High confidence*


### Annual Global Government Spending on Clinical Trials {#sec-global_government_clinical_trials_spending_annual}

**Value**: $4.50B

Annual global government spending on interventional clinical trials (~5-10% of total)

**Source**: [global-government-clinical-trial-spending-estimate](../references.qmd#global-government-clinical-trial-spending-estimate)

#### Uncertainty Range

**Technical**: 95% CI: [$3.00B, $6.00B] • Distribution: Lognormal (SE: $1.00B)

**What this means**: There's significant uncertainty here. The true value likely falls between $3.00B and $6.00B (±33%). This represents a wide range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

#### Input Distribution

{{< include ../figures/distribution-global_government_clinical_trials_spending_annual.qmd >}}

*✓ High confidence*


### Global Household Wealth {#sec-global_household_wealth_usd}

**Value**: $454T

Total global household wealth (2022/2023 estimate)

**Source**: [cs-global-wealth-report-2023](../references.qmd#cs-global-wealth-report-2023)

*✓ High confidence*


### Global Life Expectancy (2024) {#sec-global_life_expectancy_2024}

**Value**: 79 years

Global life expectancy (2024)

**Source**: [who-global-health-estimates-2024](../references.qmd#who-global-health-estimates-2024)

#### Uncertainty Range

**Technical**: Distribution: Normal (SE: 2 years)

#### Input Distribution

{{< include ../figures/distribution-global_life_expectancy_2024.qmd >}}

*✓ High confidence • 📊 Peer-reviewed • Updated 2024*


### Global Government Medical Research Spending {#sec-global_med_research_spending}

**Value**: $67.5B

Global government medical research spending

**Source**: [global-gov-med-research-spending](../references.qmd#global-gov-med-research-spending)

#### Uncertainty Range

**Technical**: 95% CI: [$54B, $81B] • Distribution: Lognormal

**What this means**: This estimate has moderate uncertainty. The true value likely falls between $54B and $81B (±20%). This represents a reasonable range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

#### Input Distribution

{{< include ../figures/distribution-global_med_research_spending.qmd >}}

*✓ High confidence*


### Global Military Spending in 2024 {#sec-global_military_spending_annual_2024}

**Value**: $2.72T

Global military spending in 2024

**Source**: [global-military-spending](../references.qmd#global-military-spending)

#### Uncertainty Range

**Technical**: 95% CI: [$2.45T, $2.99T] • Distribution: Lognormal (SE: $272B)

**What this means**: This estimate has moderate uncertainty. The true value likely falls between $2.45T and $2.99T (±10%). This represents a reasonable range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

#### Input Distribution

{{< include ../figures/distribution-global_military_spending_annual_2024.qmd >}}

*✓ High confidence*


### Global Population in 2024 {#sec-global_population_2024}

**Value**: 8.00B of people

Global population in 2024

**Source**: [global-population-8-billion](../references.qmd#global-population-8-billion)

#### Uncertainty Range

**Technical**: 95% CI: [7.80B of people, 8.20B of people] • Distribution: Lognormal

**What this means**: We're quite confident in this estimate. The true value likely falls between 7.80B of people and 8.20B of people (±2%). This represents a narrow range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

#### Input Distribution

{{< include ../figures/distribution-global_population_2024.qmd >}}

*✓ High confidence*


### Critical Mass Threshold for Social Change {#sec-global_population_activism_threshold_pct}

**Value**: 3.5%

Critical mass threshold for social change (3.5% rule)

**Source**: [3-5-rule](../references.qmd#3-5-rule)

#### Uncertainty Range

**Technical**: 95% CI: [2.5%, 4.5%] • Distribution: Lognormal

**What this means**: There's significant uncertainty here. The true value likely falls between 2.5% and 4.5% (±29%). This represents a wide range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

#### Input Distribution

{{< include ../figures/distribution-global_population_activism_threshold_pct.qmd >}}

*✓ High confidence*


### Annual Global Spending on Symptomatic Disease Treatment {#sec-global_symptomatic_disease_treatment_annual}

**Value**: $8.20T

Annual global spending on symptomatic disease treatment

**Source**: [disease-economic-burden-109t](../references.qmd#disease-economic-burden-109t)

#### Uncertainty Range

**Technical**: 95% CI: [$6.50T, $10T] • Distribution: Lognormal

**What this means**: This estimate has moderate uncertainty. The true value likely falls between $6.50T and $10T (±21%). This represents a reasonable range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

#### Input Distribution

{{< include ../figures/distribution-global_symptomatic_disease_treatment_annual.qmd >}}

*✓ High confidence*


### Estimated Total Economic Impact of Human Genome Project {#sec-human_genome_project_total_economic_impact}

**Value**: $1.00T

Estimated total economic impact of Human Genome Project

**Source**: [human-genome-and-genetic-editing](../references.qmd#human-genome-and-genetic-editing)

*✓ High confidence*


### Life Extension from Treaty Research Acceleration {#sec-life_extension_years}

**Value**: 20 years

Expected years of life extension from 1% treaty research acceleration (25x trial capacity). Bounds: 0 (complete failure) to ~150 (accident-limited lifespan minus current). Lognormal distribution allows for breakthrough scenarios.

**Source**: [longevity-escape-velocity](../references.qmd#longevity-escape-velocity)

#### Uncertainty Range

**Technical**: 95% CI: [5 years, 100 years] • Distribution: Lognormal

**What this means**: This estimate is highly uncertain. The true value likely falls between 5 years and 100 years (±238%). This represents a very wide range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

#### Input Distribution

{{< include ../figures/distribution-life_extension_years.qmd >}}

*? Low confidence*


### Maximum Annual Lobbyist Salary Range {#sec-lobbyist_salary_max}

**Value**: $2.00M

Maximum annual lobbyist salary range

**Source**: [lobbyist-statistics-dc](../references.qmd#lobbyist-statistics-dc)

*✓ High confidence*


### Minimum Annual Lobbyist Salary Range {#sec-lobbyist_salary_min_k}

**Value**: $500K

Minimum annual lobbyist salary range

**Source**: [lobbyist-statistics-dc](../references.qmd#lobbyist-statistics-dc)

*✓ High confidence*


### Return on Investment from Measles Vaccination Programs {#sec-measles_vaccination_roi}

**Value**: 14 ratio

Return on investment from measles (MMR) vaccination programs

**Source**: [measles-vaccination-roi](../references.qmd#measles-vaccination-roi)

*✓ High confidence*


### Annual Productivity Loss per Capita from Mental Health Issues {#sec-mental_health_productivity_loss_per_capita}

**Value**: $2.00K

Annual productivity loss per capita from mental health issues (beyond treatment costs)

**Source**: [mental-health-burden](../references.qmd#mental-health-burden)

*✓ High confidence*


### NIH Clinical Trials Spending Percentage {#sec-nih_clinical_trials_spending_pct}

**Value**: 3.3%

Percentage of NIH budget spent on clinical trials (3.3%)

**Source**: [nih-clinical-trials-spending-pct-3-3](../references.qmd#nih-clinical-trials-spending-pct-3-3)

#### Uncertainty Range

**Technical**: 95% CI: [2%, 5%] • Distribution: Beta

**What this means**: There's significant uncertainty here. The true value likely falls between 2% and 5% (±45%). This represents a wide range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The beta distribution means values are bounded and can skew toward one end.*

#### Input Distribution

{{< include ../figures/distribution-nih_clinical_trials_spending_pct.qmd >}}

*✓ High confidence*


### Oxford RECOVERY Trial Duration {#sec-oxford_recovery_trial_duration_months}

**Value**: 3 months

Oxford RECOVERY trial duration (found life-saving treatment in 3 months)

**Source**: [recovery-trial-82x-cost-reduction](../references.qmd#recovery-trial-82x-cost-reduction)

#### Uncertainty Range

**Technical**: Distribution: Fixed

#### Input Distribution

{{< include ../figures/distribution-oxford_recovery_trial_duration_months.qmd >}}

*✓ High confidence*


### Patient Willingness to Participate in Clinical Trials {#sec-patient_willingness_trial_participation_pct}

**Value**: 44.8%

Patient willingness to participate in drug trials (44.8% in surveys, 88% when actually approached)

**Source**: [patient-willingness-clinical-trials](../references.qmd#patient-willingness-clinical-trials)

*~ Medium confidence*


### Pharma Drug Development Cost (Current System) {#sec-pharma_drug_development_cost_current}

**Value**: $2.60B

Average cost to develop one drug in current system

**Source**: [drug-development-cost](../references.qmd#drug-development-cost)

#### Uncertainty Range

**Technical**: 95% CI: [$1.50B, $4.00B] • Distribution: Lognormal (SE: $500M)

**What this means**: There's significant uncertainty here. The true value likely falls between $1.50B and $4.00B (±48%). This represents a wide range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

#### Input Distribution

{{< include ../figures/distribution-pharma_drug_development_cost_current.qmd >}}

*✓ High confidence • 📊 Peer-reviewed*


### Pharma Average Drug Revenue (Current System) {#sec-pharma_drug_revenue_average_current}

**Value**: $6.70B

Median lifetime revenue per successful drug (study of 361 FDA-approved drugs 1995-2014, median follow-up 13.2 years)

**Source**: [pharma-drug-revenue-average](../references.qmd#pharma-drug-revenue-average)

*✓ High confidence • 📊 Peer-reviewed*


### Pharma ROI (Current System) {#sec-pharma_roi_current_system_pct}

**Value**: 1.2%

ROI for pharma R&D (2022 historic low from Deloitte study of top 20 pharma companies, down from 6.8% in 2021, recovered to 5.9% in 2024)

**Source**: [pharma-roi-current](../references.qmd#pharma-roi-current)

*✓ High confidence • 📊 Peer-reviewed*


### Pharma Drug Success Rate (Current System) {#sec-pharma_success_rate_current_pct}

**Value**: 10%

Percentage of drugs that reach market in current system

**Source**: [drug-trial-success-rate-12-pct](../references.qmd#drug-trial-success-rate-12-pct)

*✓ High confidence • 📊 Peer-reviewed*


### Phase I Safety Trial Duration {#sec-phase_1_safety_duration_years}

**Value**: 2.3 years

Phase I safety trial duration

**Source**: [bio-clinical-development-2021](../references.qmd#bio-clinical-development-2021)

*✓ High confidence • 📊 Peer-reviewed • Updated 2021*


### Phase 3 Trial Total Cost (Minimum) {#sec-phase_3_trial_cost_min}

**Value**: $20M

Phase 3 trial total cost (minimum)

**Source**: [phase-3-cost-per-trial-range](../references.qmd#phase-3-cost-per-trial-range)

*✓ High confidence*


### Return on Investment from Sustaining Polio Vaccination Assets and Integrating into Expanded Immunization Programs {#sec-polio_vaccination_roi}

**Value**: 39 ratio

Return on investment from sustaining polio vaccination assets and integrating into expanded immunization programs

**Source**: [polio-vaccination-roi](../references.qmd#polio-vaccination-roi)

*✓ High confidence*


### Political Success Probability {#sec-political_success_probability}

**Value**: 1%

Estimated probability of treaty ratification and sustained implementation. Central estimate 1% is ultra-conservative. This assumes 99% chance of failure. 

**Source**: [icbl-ottawa-treaty](../references.qmd#icbl-ottawa-treaty)

#### Uncertainty Range

**Technical**: 95% CI: [0.1%, 10%] • Distribution: Beta (SE: 2%)

**What this means**: This estimate is highly uncertain. The true value likely falls between 0.1% and 10% (±495%). This represents a very wide range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The beta distribution means values are bounded and can skew toward one end.*

#### Input Distribution

{{< include ../figures/distribution-political_success_probability.qmd >}}

*? Low confidence*


### Post-1962 Drug Approval Reduction {#sec-post_1962_drug_approval_reduction_pct}

**Value**: 70%

Reduction in new drug approvals after 1962 Kefauver-Harris Amendment (70% drop from 43→17 drugs/year)

**Source**: [post-1962-drug-approval-drop](../references.qmd#post-1962-drug-approval-drop)

*✓ High confidence • Updated 1962-1970*


### Percentage Military Spending Cut After WW2 {#sec-post_ww2_military_cut_pct}

**Value**: 30%

Percentage military spending cut after WW2 (historical precedent)

**Source**: [us-post-wwii-military-spending-cut](../references.qmd#us-post-wwii-military-spending-cut)

*✓ High confidence*


### Pre-1962 Drug Development Cost {#sec-pre_1962_drug_development_cost}

**Value**: $50M

Pre-1962 drug development cost (documented range: $10-50M in 1950s-1960s)

**Source**: [pre-1962-drug-costs-timeline](../references.qmd#pre-1962-drug-costs-timeline)

#### Uncertainty Range

**Technical**: 95% CI: [$10M, $50M] • Distribution: Lognormal

**What this means**: There's significant uncertainty here. The true value likely falls between $10M and $50M (±40%). This represents a wide range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

#### Input Distribution

{{< include ../figures/distribution-pre_1962_drug_development_cost.qmd >}}

*~ Medium confidence*


### Pre-1962 Physician Count (Unverified) {#sec-pre_1962_physician_count}

**Value**: 144k physicians

Estimated physicians conducting real-world efficacy trials pre-1962 (unverified estimate)

**Source**: [pre-1962-physician-trials](../references.qmd#pre-1962-physician-trials)

*? Low confidence*


### Total Number of Rare Diseases Globally {#sec-rare_diseases_count_global}

**Value**: 7.00k diseases

Total number of rare diseases globally

**Source**: [95-pct-diseases-no-treatment](../references.qmd#95-pct-diseases-no-treatment)

*✓ High confidence*


### Recovery Trial Cost per Patient {#sec-recovery_trial_cost_per_patient}

**Value**: $500

RECOVERY trial cost per patient

**Source**: [recovery-cost-500](../references.qmd#recovery-cost-500)

#### Uncertainty Range

**Technical**: 95% CI: [$350, $700] • Distribution: Lognormal

**What this means**: There's significant uncertainty here. The true value likely falls between $350 and $700 (±35%). This represents a wide range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

#### Input Distribution

{{< include ../figures/distribution-recovery_trial_cost_per_patient.qmd >}}

*✓ High confidence*


### Mean Age of Preventable Death from Post-Safety Efficacy Delay {#sec-regulatory_delay_mean_age_of_death}

**Value**: 62 years

Mean age of preventable death from post-safety efficacy testing regulatory delay (Phase 2-4)

**Source**: [who-global-health-estimates-2024](../references.qmd#who-global-health-estimates-2024)

#### Uncertainty Range

**Technical**: Distribution: Normal (SE: 3 years)

#### Input Distribution

{{< include ../figures/distribution-regulatory_delay_mean_age_of_death.qmd >}}

*~ Medium confidence • 📊 Peer-reviewed*


### Pre-Death Suffering Period During Post-Safety Efficacy Delay {#sec-regulatory_delay_suffering_period_years}

**Value**: 6 years

Pre-death suffering period during post-safety efficacy testing delay (average years lived with untreated condition while awaiting Phase 2-4 completion)

**Source**: [who-global-health-estimates-2024](../references.qmd#who-global-health-estimates-2024)

#### Uncertainty Range

**Technical**: 95% CI: [4 years, 9 years] • Distribution: Lognormal

**What this means**: There's significant uncertainty here. The true value likely falls between 4 years and 9 years (±42%). This represents a wide range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

#### Input Distribution

{{< include ../figures/distribution-regulatory_delay_suffering_period_years.qmd >}}

*~ Medium confidence • 📊 Peer-reviewed*


### Return on Investment from Smallpox Eradication Campaign {#sec-smallpox_eradication_roi}

**Value**: 280 ratio

Return on investment from smallpox eradication campaign

**Source**: [smallpox-eradication-roi](../references.qmd#smallpox-eradication-roi)

*✓ High confidence*


### Total Economic Benefit from Smallpox Eradication Campaign {#sec-smallpox_eradication_total_benefit}

**Value**: $1.42B

Total economic benefit from smallpox eradication campaign

**Source**: [smallpox-eradication-roi](../references.qmd#smallpox-eradication-roi)

*✓ High confidence*


### Estimated Annual Global Economic Benefit from Smoking Cessation Programs {#sec-smoking_cessation_annual_benefit}

**Value**: $12B

Estimated annual global economic benefit from smoking cessation programs

**Source**: [life-expectancy-gains-smoking-reduction](../references.qmd#life-expectancy-gains-smoking-reduction)

*✓ High confidence*


### Standard Economic Value per QALY {#sec-standard_economic_qaly_value_usd}

**Value**: $150K

Standard economic value per QALY

**Source**: [qaly-value](../references.qmd#qaly-value)

#### Uncertainty Range

**Technical**: Distribution: Normal (SE: $30K)

#### Input Distribution

{{< include ../figures/distribution-standard_economic_qaly_value_usd.qmd >}}

*✓ High confidence*


### Standard QALYs per Life Saved {#sec-standard_qalys_per_life_saved}

**Value**: 35 QALYs/life

Standard QALYs per life saved (WHO life tables)

**Source**: [qaly-value](../references.qmd#qaly-value)

#### Uncertainty Range

**Technical**: Distribution: Normal (SE: 7 QALYs/life)

#### Input Distribution

{{< include ../figures/distribution-standard_qalys_per_life_saved.qmd >}}

*✓ High confidence*


### Annual Cost of Sugar Subsidies per Person {#sec-sugar_subsidy_cost_per_person_annual}

**Value**: $10

Annual cost of sugar subsidies per person

**Source**: [sugar-subsidies-cost](../references.qmd#sugar-subsidies-cost)

*✓ High confidence*


### Switzerland's Defense Spending as Percentage of GDP {#sec-switzerland_defense_spending_pct}

**Value**: 0.7%

Switzerland's defense spending as percentage of GDP (0.7%)

**Source**: [swiss-military-budget-0-7-pct-gdp](../references.qmd#swiss-military-budget-0-7-pct-gdp)

*✓ High confidence*


### Switzerland GDP per Capita {#sec-switzerland_gdp_per_capita_k}

**Value**: $93K

Switzerland GDP per capita

**Source**: [swiss-vs-us-gdp-per-capita](../references.qmd#swiss-vs-us-gdp-per-capita)

*✓ High confidence*


### Deaths from 9/11 Terrorist Attacks {#sec-terrorism_deaths_911}

**Value**: 3.00k deaths

Deaths from 9/11 terrorist attacks

**Source**: [chance-of-dying-from-terrorism-1-in-30m](../references.qmd#chance-of-dying-from-terrorism-1-in-30m)

*✓ High confidence*


### Thalidomide Cases Worldwide {#sec-thalidomide_cases_worldwide}

**Value**: 15.0k cases

Total thalidomide birth defect cases worldwide (1957-1962)

**Source**: [thalidomide-scandal](../references.qmd#thalidomide-scandal)

#### Uncertainty Range

**Technical**: 95% CI: [10.0k cases, 20.0k cases] • Distribution: Lognormal

**What this means**: There's significant uncertainty here. The true value likely falls between 10.0k cases and 20.0k cases (±33%). This represents a wide range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

#### Input Distribution

{{< include ../figures/distribution-thalidomide_cases_worldwide.qmd >}}

*~ Medium confidence*


### Thalidomide Disability Weight {#sec-thalidomide_disability_weight}

**Value**: 0.4 ratio

Disability weight for thalidomide survivors (limb deformities, organ damage)

**Source**: [thalidomide-survivors-health](../references.qmd#thalidomide-survivors-health)

#### Uncertainty Range

**Technical**: 95% CI: [0.32 ratio, 0.48 ratio] • Distribution: Lognormal

**What this means**: This estimate has moderate uncertainty. The true value likely falls between 0.32 ratio and 0.48 ratio (±20%). This represents a reasonable range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

#### Input Distribution

{{< include ../figures/distribution-thalidomide_disability_weight.qmd >}}

*~ Medium confidence*


### Thalidomide Mortality Rate {#sec-thalidomide_mortality_rate}

**Value**: 40%

Mortality rate for thalidomide-affected infants (died within first year)

**Source**: [thalidomide-scandal](../references.qmd#thalidomide-scandal)

#### Uncertainty Range

**Technical**: 95% CI: [35%, 45%] • Distribution: Lognormal

**What this means**: This estimate has moderate uncertainty. The true value likely falls between 35% and 45% (±13%). This represents a reasonable range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

#### Input Distribution

{{< include ../figures/distribution-thalidomide_mortality_rate.qmd >}}

*✓ High confidence*


### Thalidomide Survivor Lifespan {#sec-thalidomide_survivor_lifespan}

**Value**: 60 years

Average lifespan for thalidomide survivors

**Source**: [thalidomide-survivors-health](../references.qmd#thalidomide-survivors-health)

#### Uncertainty Range

**Technical**: 95% CI: [50 years, 70 years] • Distribution: Lognormal

**What this means**: This estimate has moderate uncertainty. The true value likely falls between 50 years and 70 years (±17%). This represents a reasonable range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

#### Input Distribution

{{< include ../figures/distribution-thalidomide_survivor_lifespan.qmd >}}

*~ Medium confidence*


### US Population Share 1960 {#sec-thalidomide_us_population_share_1960}

**Value**: 6%

US share of world population in 1960

**Source**: [us-census-world-population-1960](../references.qmd#us-census-world-population-1960)

#### Uncertainty Range

**Technical**: 95% CI: [5.5%, 6.5%] • Distribution: Lognormal

**What this means**: We're quite confident in this estimate. The true value likely falls between 5.5% and 6.5% (±8%). This represents a narrow range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

#### Input Distribution

{{< include ../figures/distribution-thalidomide_us_population_share_1960.qmd >}}

*✓ High confidence*


### Phase 3 Cost per Patient {#sec-traditional_phase3_cost_per_patient}

**Value**: $80K

Phase 3 cost per patient (median)

**Source**: [phase-3-cost-per-patient-113k](../references.qmd#phase-3-cost-per-patient-113k)

*✓ High confidence*


### Example Phase 3 Trial Cost per Patient {#sec-traditional_phase3_cost_per_patient_example_48k}

**Value**: $48K

Example Phase 3 trial cost per patient ($48K)

**Source**: [clinical-trial-cost-per-patient](../references.qmd#clinical-trial-cost-per-patient)

*✓ High confidence*


### FDA Cited Phase 3 Cost per Patient {#sec-traditional_phase3_cost_per_patient_fda_example_41k}

**Value**: $41K

FDA cited Phase 3 cost per patient ($41K)

**Source**: [trial-costs-fda-study](../references.qmd#trial-costs-fda-study)

*✓ High confidence*


### Traditional FDA Drug Development Timeline {#sec-treatment_acceleration_years_current}

**Value**: 17 years

Traditional FDA drug development timeline

**Source**: [fda-approval-timeline-10-years](../references.qmd#fda-approval-timeline-10-years)

*✓ High confidence*


### Cost Reduction Factor Demonstrated by Recovery Trial {#sec-trial_cost_reduction_factor}

**Value**: 82 ratio

Cost reduction factor demonstrated by RECOVERY trial

**Source**: [recovery-trial-82x-cost-reduction](../references.qmd#recovery-trial-82x-cost-reduction)

#### Uncertainty Range

**Technical**: 95% CI: [20 ratio, 150 ratio] • Distribution: Lognormal (SE: 20 ratio)

**What this means**: This estimate is highly uncertain. The true value likely falls between 20 ratio and 150 ratio (±79%). This represents a very wide range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

#### Input Distribution

{{< include ../figures/distribution-trial_cost_reduction_factor.qmd >}}

*✓ High confidence*


### Typical CEO Hourly Rate {#sec-typical_ceo_hourly_rate}

**Value**: $10K

Typical CEO hourly rate

**Source**: [ceo-compensation](../references.qmd#ceo-compensation)

*✓ High confidence*


### US Alzheimer's Annual Cost {#sec-us_alzheimers_annual_cost}

**Value**: $355B

Annual US cost of Alzheimer's disease (direct and indirect)

**Source**: [disease-cost-alzheimers-1300b](../references.qmd#disease-cost-alzheimers-1300b)

#### Uncertainty Range

**Technical**: 95% CI: [$302B, $408B] • Distribution: Lognormal

**What this means**: This estimate has moderate uncertainty. The true value likely falls between $302B and $408B (±15%). This represents a reasonable range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

#### Input Distribution

{{< include ../figures/distribution-us_alzheimers_annual_cost.qmd >}}

*✓ High confidence • 📊 Peer-reviewed*


### US Cancer Annual Cost {#sec-us_cancer_annual_cost}

**Value**: $208B

Annual US cost of cancer (direct and indirect)

**Source**: [disease-cost-cancer-1800b](../references.qmd#disease-cost-cancer-1800b)

#### Uncertainty Range

**Technical**: 95% CI: [$177B, $239B] • Distribution: Lognormal

**What this means**: This estimate has moderate uncertainty. The true value likely falls between $177B and $239B (±15%). This represents a reasonable range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

#### Input Distribution

{{< include ../figures/distribution-us_cancer_annual_cost.qmd >}}

*✓ High confidence • 📊 Peer-reviewed*


### US Annual Chronic Disease Spending {#sec-us_chronic_disease_spending_annual}

**Value**: $4.10T

US annual chronic disease spending

**Source**: [us-chronic-disease-spending](../references.qmd#us-chronic-disease-spending)

#### Uncertainty Range

**Technical**: 95% CI: [$3.30T, $5.00T] • Distribution: Lognormal

**What this means**: This estimate has moderate uncertainty. The true value likely falls between $3.30T and $5.00T (±21%). This represents a reasonable range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

#### Input Distribution

{{< include ../figures/distribution-us_chronic_disease_spending_annual.qmd >}}

*✓ High confidence*


### US Diabetes Annual Cost {#sec-us_diabetes_annual_cost}

**Value**: $327B

Annual US cost of diabetes (direct and indirect)

**Source**: [disease-cost-diabetes-1500b](../references.qmd#disease-cost-diabetes-1500b)

#### Uncertainty Range

**Technical**: 95% CI: [$278B, $376B] • Distribution: Lognormal

**What this means**: This estimate has moderate uncertainty. The true value likely falls between $278B and $376B (±15%). This represents a reasonable range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

#### Input Distribution

{{< include ../figures/distribution-us_diabetes_annual_cost.qmd >}}

*✓ High confidence • 📊 Peer-reviewed*


### US Heart Disease Annual Cost {#sec-us_heart_disease_annual_cost}

**Value**: $363B

Annual US cost of heart disease and stroke (direct and indirect)

**Source**: [disease-cost-heart-disease-2100b](../references.qmd#disease-cost-heart-disease-2100b)

#### Uncertainty Range

**Technical**: 95% CI: [$309B, $417B] • Distribution: Lognormal

**What this means**: This estimate has moderate uncertainty. The true value likely falls between $309B and $417B (±15%). This represents a reasonable range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

#### Input Distribution

{{< include ../figures/distribution-us_heart_disease_annual_cost.qmd >}}

*✓ High confidence • 📊 Peer-reviewed*


### US Mental Health Costs {#sec-us_mental_health_cost_annual}

**Value**: $350B

US mental health costs (treatment + productivity loss)

**Source**: [mental-health-burden](../references.qmd#mental-health-burden)

#### Uncertainty Range

**Technical**: 95% CI: [$260B, $450B] • Distribution: Lognormal

**What this means**: There's significant uncertainty here. The true value likely falls between $260B and $450B (±27%). This represents a wide range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

#### Input Distribution

{{< include ../figures/distribution-us_mental_health_cost_annual.qmd >}}

*✓ High confidence*


### US Military Spending as Percentage of GDP {#sec-us_military_spending_pct_gdp}

**Value**: 3.5%

US military spending as percentage of GDP (2024)

**Source**: [us-military-budget-3-5-pct-gdp](../references.qmd#us-military-budget-3-5-pct-gdp)

*✓ High confidence*


### US Population in 2024 {#sec-us_population_2024}

**Value**: 335M people

US population in 2024

**Source**: [us-voter-population](../references.qmd#us-voter-population)

#### Uncertainty Range

**Technical**: 95% CI: [330M people, 340M people] • Distribution: Lognormal

**What this means**: We're quite confident in this estimate. The true value likely falls between 330M people and 340M people (±1%). This represents a narrow range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

#### Input Distribution

{{< include ../figures/distribution-us_population_2024.qmd >}}

*✓ High confidence*


### Value of Statistical Life {#sec-value_of_statistical_life}

**Value**: $10M

Value of Statistical Life (conservative estimate)

**Source**: [dot-vsl-13-6m](../references.qmd#dot-vsl-13-6m)

#### Uncertainty Range

**Technical**: 95% CI: [$5.00M, $15M] • Distribution: Gamma (SE: $3.00M)

**What this means**: There's significant uncertainty here. The true value likely falls between $5.00M and $15M (±50%). This represents a wide range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The gamma distribution means values follow a specific statistical pattern.*

#### Input Distribution

{{< include ../figures/distribution-value_of_statistical_life.qmd >}}

*✓ High confidence*


### Vitamin A Supplementation Cost per DALY {#sec-vitamin_a_cost_per_daly}

**Value**: $37

Cost per DALY for vitamin A supplementation programs (India: $23-50; Africa: $40-255; wide variation by region and baseline VAD prevalence). Using India midpoint as conservative estimate.

**Source**: [vitamin-a-cost-per-daly](../references.qmd#vitamin-a-cost-per-daly)

*~ Medium confidence*


### Estimated Annual Global Economic Benefit from Water Fluoridation Programs {#sec-water_fluoridation_annual_benefit}

**Value**: $800M

Estimated annual global economic benefit from water fluoridation programs

**Source**: [clean-water-sanitation-roi](../references.qmd#clean-water-sanitation-roi)

*✓ High confidence*


### Return on Investment from Water Fluoridation Programs {#sec-water_fluoridation_roi}

**Value**: 23 ratio

Return on investment from water fluoridation programs

**Source**: [clean-water-sanitation-roi](../references.qmd#clean-water-sanitation-roi)

*✓ High confidence*


### Cost-Effectiveness Threshold ($50,000/QALY) {#sec-who_qaly_threshold_cost_effective}

**Value**: $50K

Cost-effectiveness threshold widely used in US health economics ($50,000/QALY, from 1980s dialysis costs)

**Source**: [who-cost-effectiveness-threshold](../references.qmd#who-cost-effectiveness-threshold)

*✓ High confidence*


### Percentage of Workforce Experiencing Productivity Loss from Chronic Illness {#sec-workforce_with_productivity_loss}

**Value**: 28%

Percentage of workforce experiencing productivity loss from chronic illness (28%)

**Source**: [chronic-illness-workforce-productivity-loss](../references.qmd#chronic-illness-workforce-productivity-loss)

*✓ High confidence*


## Core Definitions {#sec-definitions}

Fundamental parameters and constants used throughout the analysis.

### Celebrity and Influencer Endorsements {#sec-campaign_celebrity_endorsement}

**Value**: $15M

Celebrity and influencer endorsements

*Core definition*


### Community Organizing and Ambassador Program Budget {#sec-campaign_community_organizing}

**Value**: $30M

Community organizing and ambassador program budget

*Core definition*


### Contingency Fund for Unexpected Costs {#sec-campaign_contingency}

**Value**: $50M

Contingency fund for unexpected costs

#### Uncertainty Range

**Technical**: 95% CI: [$30M, $80M] • Distribution: Uniform

**What this means**: There's significant uncertainty here. The true value likely falls between $30M and $80M (±50%). This represents a wide range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The uniform distribution means any value in the range is equally likely.*

*Core definition*


### Defense Industry Conversion Program {#sec-campaign_defense_conversion}

**Value**: $50M

Defense industry conversion program

#### Uncertainty Range

**Technical**: 95% CI: [$40M, $70M] • Distribution: Lognormal

**What this means**: There's significant uncertainty here. The true value likely falls between $40M and $70M (±30%). This represents a wide range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

*Core definition*


### Budget for Co-Opting Defense Industry Lobbyists {#sec-campaign_defense_lobbyist_budget}

**Value**: $50M

Budget for co-opting defense industry lobbyists

*Core definition*


### Healthcare Industry Alignment and Partnerships {#sec-campaign_healthcare_alignment}

**Value**: $35M

Healthcare industry alignment and partnerships

*Core definition*


### Campaign Operational Infrastructure {#sec-campaign_infrastructure}

**Value**: $20M

Campaign operational infrastructure

*Core definition*


### AI-Assisted Legal Work Budget {#sec-campaign_legal_ai_budget}

**Value**: $50M

AI-assisted legal work budget

*Core definition*


### Legal Defense Fund {#sec-campaign_legal_defense}

**Value**: $20M

Legal defense fund

*Core definition*


### Legal Drafting and Compliance Work {#sec-campaign_legal_work}

**Value**: $60M

Legal drafting and compliance work

#### Uncertainty Range

**Technical**: 95% CI: [$50M, $80M] • Distribution: Lognormal

**What this means**: This estimate has moderate uncertainty. The true value likely falls between $50M and $80M (±25%). This represents a reasonable range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

*Core definition*


### EU Lobbying Campaign Budget {#sec-campaign_lobbying_eu}

**Value**: $40M

EU lobbying campaign budget

*Core definition*


### G20 Countries Lobbying Budget {#sec-campaign_lobbying_g20_millions}

**Value**: $35M

G20 countries lobbying budget

*Core definition*


### US Lobbying Campaign Budget {#sec-campaign_lobbying_us}

**Value**: $50M

US lobbying campaign budget

*Core definition*


### Maximum Mass Media Campaign Budget {#sec-campaign_media_budget_max}

**Value**: $1.00B

Maximum mass media campaign budget

*Core definition*


### Minimum Mass Media Campaign Budget {#sec-campaign_media_budget_min}

**Value**: $500M

Minimum mass media campaign budget

*Core definition*


### Opposition Research and Rapid Response {#sec-campaign_opposition_research}

**Value**: $25M

Opposition research and rapid response

*Core definition*


### Phase 1 Campaign Budget {#sec-campaign_phase1_budget}

**Value**: $200M

Phase 1 campaign budget (Foundation, Year 1)

*Core definition*


### Phase 2 Campaign Budget {#sec-campaign_phase2_budget}

**Value**: $500M

Phase 2 campaign budget (Scale & Momentum, Years 2-3)

*Core definition*


### Pilot Program Testing in Small Countries {#sec-campaign_pilot_programs}

**Value**: $30M

Pilot program testing in small countries

*Core definition*


### Voting Platform and Technology Development {#sec-campaign_platform_development}

**Value**: $35M

Voting platform and technology development

#### Uncertainty Range

**Technical**: 95% CI: [$25M, $50M] • Distribution: Lognormal

**What this means**: There's significant uncertainty here. The true value likely falls between $25M and $50M (±36%). This represents a wide range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

*Core definition*


### Regulatory Compliance and Navigation {#sec-campaign_regulatory_navigation}

**Value**: $20M

Regulatory compliance and navigation

*Core definition*


### Scaling Preparation and Blueprints {#sec-campaign_scaling_prep}

**Value**: $30M

Scaling preparation and blueprints

*Core definition*


### Campaign Core Team Staff Budget {#sec-campaign_staff_budget}

**Value**: $40M

Campaign core team staff budget

*Core definition*


### Super PAC Campaign Expenditures {#sec-campaign_super_pac_budget}

**Value**: $30M

Super PAC campaign expenditures

*Core definition*


### Tech Industry Partnerships and Infrastructure {#sec-campaign_tech_partnerships}

**Value**: $25M

Tech industry partnerships and infrastructure

*Core definition*


### Post-Victory Treaty Implementation Support {#sec-campaign_treaty_implementation}

**Value**: $40M

Post-victory treaty implementation support

#### Uncertainty Range

**Technical**: 95% CI: [$30M, $55M] • Distribution: Lognormal

**What this means**: There's significant uncertainty here. The true value likely falls between $30M and $55M (±31%). This represents a wide range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

*Core definition*


### Viral Marketing Content Creation Budget {#sec-campaign_viral_content_budget}

**Value**: $40M

Viral marketing content creation budget

*Core definition*


### Annual Cost of Unpaid Caregiving {#sec-caregiver_cost_annual}

**Value**: $6.00K

Annual cost of unpaid caregiving (replacement cost method)

*Core definition*


### Childhood Vaccination Cost per DALY (Estimated) {#sec-childhood_vaccination_cost_per_daly}

**Value**: $30

Estimated cost per DALY for US childhood vaccination programs. Note: US cost-effectiveness studies primarily use cost per QALY (Quality-Adjusted Life Year) rather than cost per DALY. This estimate is derived from program costs and benefits for comparison purposes only.

*Core definition*


### Concentrated Interest Sector Market Cap {#sec-concentrated_interest_sector_market_cap_usd}

**Value**: $5.00T

Estimated combined market capitalization of concentrated interest opposition (defense, fossil fuel, etc.)

*Core definition*


### Current Patient Participation Rate in Clinical Trials {#sec-current_patient_participation_rate}

**Value**: 0.0792%

Current patient participation rate in clinical trials (0.08% = 1.9M participants / 2.4B disease patients)

*Core definition*


### Days Per Year {#sec-days_per_year}

**Value**: 365

*Core definition*


### Mid-Range Funding for Commercial Dct Platform {#sec-dct_platform_funding_medium}

**Value**: $500M

Mid-range funding for commercial DCT platform

*Core definition*


### Percentage of Budget Defense Sector Keeps Under 1% treaty {#sec-defense_sector_retention_pct}

**Value**: 99%

Percentage of budget defense sector keeps under 1% treaty

*Core definition*


### Years to Reach Full dFDA Adoption {#sec-dfda_npv_adoption_ramp_years}

**Value**: 5 years

Years to reach full dFDA adoption

*Core definition*


### dFDA Core Platform Annual OPEX {#sec-dfda_npv_annual_opex}

**Value**: $18.9M

dFDA core platform annual opex (midpoint of $11-26.5M)

#### Uncertainty Range

**Technical**: 95% CI: [$11M, $26.5M] • Distribution: Lognormal

**What this means**: There's significant uncertainty here. The true value likely falls between $11M and $26.5M (±41%). This represents a wide range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

*Core definition*


### dFDA Core Platform Build Cost {#sec-dfda_npv_upfront_cost}

**Value**: $40M

dFDA core platform build cost

#### Uncertainty Range

**Technical**: 95% CI: [$25M, $65M] • Distribution: Lognormal

**What this means**: There's significant uncertainty here. The true value likely falls between $25M and $65M (±50%). This represents a wide range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

*Core definition*


### dFDA Community Support Costs {#sec-dfda_opex_community}

**Value**: $2.00M

dFDA community support costs

#### Uncertainty Range

**Technical**: 95% CI: [$1.00M, $3.00M] • Distribution: Lognormal

**What this means**: There's significant uncertainty here. The true value likely falls between $1.00M and $3.00M (±50%). This represents a wide range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

*Core definition*


### dFDA Infrastructure Costs {#sec-dfda_opex_infrastructure}

**Value**: $8.00M

dFDA infrastructure costs (cloud, security)

#### Uncertainty Range

**Technical**: 95% CI: [$5.00M, $12M] • Distribution: Lognormal

**What this means**: There's significant uncertainty here. The true value likely falls between $5.00M and $12M (±44%). This represents a wide range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

*Core definition*


### dFDA Overhead Percentage of Treaty Funding {#sec-dfda_opex_pct_of_treaty_funding}

**Value**: 0.147%

Percentage of treaty funding allocated to dFDA platform overhead

*Core definition*


### dFDA Maintenance Costs {#sec-dfda_opex_platform_maintenance}

**Value**: $15M

dFDA maintenance costs

#### Uncertainty Range

**Technical**: 95% CI: [$10M, $22M] • Distribution: Lognormal

**What this means**: There's significant uncertainty here. The true value likely falls between $10M and $22M (±40%). This represents a wide range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

*Core definition*


### dFDA Regulatory Coordination Costs {#sec-dfda_opex_regulatory}

**Value**: $5.00M

dFDA regulatory coordination costs

#### Uncertainty Range

**Technical**: 95% CI: [$3.00M, $8.00M] • Distribution: Lognormal

**What this means**: There's significant uncertainty here. The true value likely falls between $3.00M and $8.00M (±50%). This represents a wide range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

*Core definition*


### dFDA Staff Costs {#sec-dfda_opex_staff}

**Value**: $10M

dFDA staff costs (minimal, AI-assisted)

#### Uncertainty Range

**Technical**: 95% CI: [$7.00M, $15M] • Distribution: Lognormal

**What this means**: There's significant uncertainty here. The true value likely falls between $7.00M and $15M (±40%). This represents a wide range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

*Core definition*


### dFDA Target Cost per Patient in USD {#sec-dfda_target_cost_per_patient_usd}

**Value**: $1.00K

Target cost per patient in USD (same as DFDA_TARGET_COST_PER_PATIENT but in dollars)

*Core definition*


### dFDA One-Time Build Cost {#sec-dfda_upfront_build}

**Value**: $40M

dFDA one-time build cost (central estimate)

*Core definition*


### dFDA One-Time Build Cost (Maximum) {#sec-dfda_upfront_build_max}

**Value**: $46M

dFDA one-time build cost (high estimate)

*Core definition*


### DIH Broader Initiatives Annual OPEX {#sec-dih_npv_annual_opex_initiatives}

**Value**: $21.1M

DIH broader initiatives annual opex (medium case)

#### Uncertainty Range

**Technical**: 95% CI: [$14M, $32M] • Distribution: Lognormal

**What this means**: There's significant uncertainty here. The true value likely falls between $14M and $32M (±43%). This represents a wide range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

*Core definition*


### DIH Broader Initiatives Upfront Cost {#sec-dih_npv_upfront_cost_initiatives}

**Value**: $230M

DIH broader initiatives upfront cost (medium case)

#### Uncertainty Range

**Technical**: 95% CI: [$150M, $350M] • Distribution: Lognormal

**What this means**: There's significant uncertainty here. The true value likely falls between $150M and $350M (±44%). This represents a wide range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

*Core definition*


### Medical Research Percentage of Treaty Funding {#sec-dih_treasury_medical_research_pct}

**Value**: 80%

Percentage of treaty funding allocated to medical research (after bond payouts and IAB incentives)

*Core definition*


### Patient Trial Subsidies Percentage of Treaty Funding {#sec-dih_treasury_trial_subsidies_pct}

**Value**: 79.9%

Percentage of treaty funding going directly to patient trial subsidies

*Core definition*


### Percentage of Caregiving for Treatable Disease Conditions {#sec-disease_related_caregiver_pct}

**Value**: 40%

Percentage of caregiving for treatable disease conditions (vs aging, disability, children)

*Core definition*


### Ratio of Annual Disease Deaths to 9/11 Terrorism Deaths {#sec-disease_vs_terrorism_deaths_ratio}

**Value**: 18.4k ratio

Ratio of annual disease deaths to 9/11 terrorism deaths

*Core definition*


### Ratio of Annual Disease Deaths to War Deaths {#sec-disease_vs_war_deaths_ratio}

**Value**: 225 ratio

Ratio of annual disease deaths to war deaths

*Core definition*


### Lifetime Benefit for Age 30 Baseline Scenario {#sec-effective_hourly_rate_lifetime_benefit}

**Value**: $4.30M

Lifetime benefit for age 30 baseline scenario ($4.3M)

*Core definition*


### Eventually Avoidable Death Percentage {#sec-eventually_avoidable_death_pct}

**Value**: 92.6%

Percentage of deaths that are eventually avoidable with sufficient biomedical research and technological advancement

*Core definition*


### Minimum Investment for Family Offices {#sec-family_office_investment_min}

**Value**: $5.00M

Minimum investment for family offices

*Core definition*


### Fundamentally Unavoidable Death Percentage {#sec-fundamentally_unavoidable_death_pct}

**Value**: 7.37%

Percentage of deaths that are fundamentally unavoidable even with perfect biotechnology (primarily accidents). Calculated as Σ(disease_burden × (1 - max_cure_potential)) across all disease categories.

*Core definition*


### Hours Per Day {#sec-hours_per_day}

**Value**: 24

*Core definition*


### Hours Per Year {#sec-hours_per_year}

**Value**: 8.76k

*Core definition*


### Bootstrap Campaign Cost (Base Case) {#sec-iab_bootstrap_campaign_cost_base_usd}

**Value**: $100M

Base case estimate for bootstrap campaign cost

*Core definition*


### Bootstrap Campaign Cost (Conservative) {#sec-iab_bootstrap_campaign_cost_conservative_usd}

**Value**: $200M

Conservative estimate for bootstrap campaign cost

*Core definition*


### Bootstrap Campaign Cost (Optimistic) {#sec-iab_bootstrap_campaign_cost_optimistic_usd}

**Value**: $50M

Optimistic estimate for bootstrap campaign cost

*Core definition*


### IAB Mechanism Benefit-Cost Ratio {#sec-iab_mechanism_benefit_cost_ratio}

**Value**: 303 ratio

Benefit-Cost Ratio of the IAB mechanism itself

*Core definition*


### IAB Political Incentive Funding Percentage {#sec-iab_political_incentive_funding_pct}

**Value**: 10%

Percentage of treaty funding allocated to Incentive Alignment Bond mechanism for political incentives (independent expenditures/PACs, post-office fellowships, Public Good Score infrastructure)

#### Uncertainty Range

**Technical**: Distribution: Fixed

*Core definition*


### Minimum Investment for Institutional Investors {#sec-institutional_investor_min}

**Value**: $10M

Minimum investment for institutional investors

*Core definition*


### Maximum Bond Investment for Lobbyist Incentives {#sec-lobbyist_bond_investment_max}

**Value**: $20M

Maximum bond investment for lobbyist incentives

*Core definition*


### Minutes Per Hour {#sec-minutes_per_hour}

**Value**: 60

*Core definition*


### Months Per Year {#sec-months_per_year}

**Value**: 12

*Core definition*


### Standard Discount Rate for NPV Analysis {#sec-npv_discount_rate_standard}

**Value**: 3%

Standard discount rate for NPV analysis (3% annual, social discount rate)

#### Uncertainty Range

**Technical**: Distribution: Fixed

*Core definition*


### Standard Time Horizon for NPV Analysis {#sec-npv_time_horizon_years}

**Value**: 10 years

Standard time horizon for NPV analysis

#### Uncertainty Range

**Technical**: Distribution: Fixed

*Core definition*


### Direct Fiscal Savings from 1% Military Spending Reduction {#sec-peace_dividend_direct_fiscal_savings}

**Value**: $27.2B

Direct fiscal savings from 1% military spending reduction (high confidence)

*Core definition*


### Pre-1962 Validation Years {#sec-pre_1962_validation_years}

**Value**: 77 years

Years of empirical validation for physician-led pragmatic trials (1883-1960)

*Core definition*


### Seconds Per Minute {#sec-seconds_per_minute}

**Value**: 60

*Core definition*


### Seconds Per Year {#sec-seconds_per_year}

**Value**: 31.5M

*Core definition*


### Total Words in the Book {#sec-total_book_words}

**Value**: 171k words

Total words in the book

*Core definition*


### Annual Funding from 1% of Global Military Spending Redirected to DIH {#sec-treaty_annual_funding}

**Value**: $27.2B

Annual funding from 1% of global military spending redirected to DIH

*Core definition*


### Political Lobbying Campaign: Direct Lobbying, Super Pacs, Opposition Research, Staff, Legal/Compliance {#sec-treaty_campaign_budget_lobbying}

**Value**: $650M

Political lobbying campaign: direct lobbying (US/EU/G20), Super PACs, opposition research, staff, legal/compliance (exceeds pharma $300M + MIC $150M)

#### Uncertainty Range

**Technical**: 95% CI: [$325M, $1.30B] • Distribution: Lognormal

**What this means**: This estimate is highly uncertain. The true value likely falls between $325M and $1.30B (±75%). This represents a very wide range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

*Core definition*


### Global Referendum Campaign: Ads, Media, Partnerships, Staff, Legal/Compliance {#sec-treaty_campaign_budget_referendum}

**Value**: $300M

Global referendum campaign (get 208M votes): ads, media, partnerships, staff, legal/compliance

#### Uncertainty Range

**Technical**: 95% CI: [$180M, $500M] • Distribution: Lognormal

**What this means**: This estimate is highly uncertain. The true value likely falls between $180M and $500M (±53%). This represents a very wide range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

*Core definition*


### Reserve Fund / Contingency Buffer {#sec-treaty_campaign_budget_reserve}

**Value**: $50M

Reserve fund / contingency buffer

#### Uncertainty Range

**Technical**: 95% CI: [$20M, $100M] • Distribution: Lognormal

**What this means**: This estimate is highly uncertain. The true value likely falls between $20M and $100M (±80%). This represents a very wide range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The lognormal distribution means values can't go negative and have a longer tail toward higher values (common for costs and populations).*

*Core definition*


### Campaign Budget for Super Pacs and Political Lobbying {#sec-treaty_campaign_budget_super_pacs}

**Value**: $800M

Campaign budget for Super PACs and political lobbying

*Core definition*


### Treaty Campaign Duration {#sec-treaty_campaign_duration_years}

**Value**: 4 years

Treaty campaign duration (3-5 year range, using midpoint)

#### Uncertainty Range

**Technical**: 95% CI: [3 years, 5 years] • Distribution: Triangular

**What this means**: This estimate has moderate uncertainty. The true value likely falls between 3 years and 5 years (±25%). This represents a reasonable range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The triangular distribution means values cluster around a most-likely point but can range higher or lower.*

*Core definition*


### Base Case Viral Referendum Budget {#sec-treaty_campaign_viral_referendum_base_case}

**Value**: $140M

Base case viral referendum budget (assumes flat $0.50/vote, optimistic)

*Core definition*


### Realistic Viral Referendum Budget {#sec-treaty_campaign_viral_referendum_realistic}

**Value**: $220M

Realistic viral referendum budget (moderate tiered pricing)

*Core definition*


### Worst-Case Viral Referendum Budget {#sec-treaty_campaign_viral_referendum_worst_case}

**Value**: $406M

Worst-case viral referendum budget (tiered pricing with increasing marginal costs)

*Core definition*


### 1% Reduction in Military Spending/War Costs from Treaty {#sec-treaty_reduction_pct}

**Value**: 1%

1% reduction in military spending/war costs from treaty

#### Uncertainty Range

**Technical**: Distribution: Fixed

*Core definition*


### dFDA Trial Cost Reduction Percentage {#sec-trial_cost_reduction_pct}

**Value**: 50%

Trial cost reduction percentage (50% baseline, conservative)

#### Uncertainty Range

**Technical**: 95% CI: [40%, 65%] • Distribution: Beta

**What this means**: This estimate has moderate uncertainty. The true value likely falls between 40% and 65% (±25%). This represents a reasonable range that our Monte Carlo simulations account for when calculating overall uncertainty in the results.

*The beta distribution means values are bounded and can skew toward one end.*

*Core definition*


### Annual VICTORY Incentive Alignment Bond Payout {#sec-victory_bond_annual_payout}

**Value**: $2.72B

Annual VICTORY bond payout (treaty funding × bond percentage)

*Core definition*


### Annual Return Percentage for VICTORY Incentive Alignment Bondholders {#sec-victory_bond_annual_return_pct}

**Value**: 272%

Annual return percentage for VICTORY bondholders

*Core definition*


### Percentage of Captured Dividend Funding VICTORY Incentive Alignment Bonds {#sec-victory_bond_funding_pct}

**Value**: 10%

Percentage of captured dividend funding VICTORY bonds (10%)

#### Uncertainty Range

**Technical**: Distribution: Fixed

*Core definition*

